Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 790 articles:
HTML format



Single Articles


    July 2021
  1. ZHAO XY, Xu ZL, Mo XD, Chen YH, et al
    Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01351.
    PubMed    


  2. KLEINSTERN G, Weinberg JB, Parikh SA, Braggio E, et al
    Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01344.
    PubMed     Abstract available


  3. VAN DER WERF I, Wojtuszkiewicz A, Yao H, Sciarrillo R, et al
    Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
    Leukemia. 2021 Jul 8. pii: 10.1038/s41375-021-01340.
    PubMed    


  4. BOER JM, Valsecchi MG, Hormann FM, Antic Z, et al
    Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study.
    Leukemia. 2021 Jul 1. pii: 10.1038/s41375-021-01333.
    PubMed    


    June 2021
  5. SIMONETTI G, Mengucci C, Padella A, Fonzi E, et al
    Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
    Leukemia. 2021 Jun 30. pii: 10.1038/s41375-021-01318.
    PubMed     Abstract available


  6. THOMAS KR, Allenspach EJ, Camp ND, Wray-Dutra MN, et al
    Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
    Leukemia. 2021 Jun 30. pii: 10.1038/s41375-021-01326.
    PubMed     Abstract available


  7. TAJ MM, Moorman AV, Hamadeh L, Petit A, et al
    Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols.
    Leukemia. 2021 Jun 28. pii: 10.1038/s41375-021-01334.
    PubMed    


  8. BEHNERT A, Meyer J, Parsa JY, Hechmer A, et al
    Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples.
    Leukemia. 2021 Jun 28. pii: 10.1038/s41375-021-01331.
    PubMed    


  9. RENNEVILLE A, Patnaik MM, Chan O, Padron E, et al
    Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
    Leukemia. 2021 Jun 26. pii: 10.1038/s41375-021-01330.
    PubMed     Abstract available


  10. TOKSVANG LN, Grell K, Nersting J, Degn M, et al
    DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
    Leukemia. 2021 Jun 26. pii: 10.1038/s41375-021-01182.
    PubMed     Abstract available


  11. SHORT NJ, Kantarjian H, Jabbour E
    Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
    Leukemia. 2021 Jun 25. pii: 10.1038/s41375-021-01277.
    PubMed     Abstract available


  12. WIERDA WG, Rawstron A, Cymbalista F, Badoux X, et al
    Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
    Leukemia. 2021 Jun 24. pii: 10.1038/s41375-021-01241.
    PubMed     Abstract available


  13. ABDALLAH MG, Niibori-Nambu A, Morii M, Yokomizo T, et al
    RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner.
    Leukemia. 2021 Jun 19. pii: 10.1038/s41375-021-01268.
    PubMed    


  14. NISHIDA Y, Zhao R, Heese LE, Akiyama H, et al
    Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
    Leukemia. 2021 Jun 14. pii: 10.1038/s41375-021-01308.
    PubMed     Abstract available


  15. LI Z, Jiang N, Lim EH, Chin WHN, et al
    Role of transcriptome sequencing in clinical diagnosis of B-cell acute lymphoblastic leukemia.
    Leukemia. 2021 Jun 10. pii: 10.1038/s41375-021-01185.
    PubMed    


  16. KANTARJIAN HM, Hughes TP, Larson RA, Kim DW, et al
    Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
    Leukemia. 2021 Jun 9. pii: 10.1038/s41375-021-01306.
    PubMed    


  17. DHAKAL B, Patel S, Girnius S, Bachegowda L, et al
    Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
    Leukemia. 2021 Jun 5. pii: 10.1038/s41375-021-01304.
    PubMed    


  18. WIEDUWILT MJ, Stock W, Advani A, Luger S, et al
    Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: an
    Leukemia. 2021 Jun 4. pii: 10.1038/s41375-021-01303.
    PubMed    


  19. KIM D, Park G, Huuhtanen J, Ghimire B, et al
    STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation.
    Leukemia. 2021 Jun 1. pii: 10.1038/s41375-021-01296.
    PubMed     Abstract available


  20. MAYANSKIY N, Luchkina P, Fedorova N, Lebedin Y, et al
    Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients.
    Leukemia. 2021;35:1820-1822.
    PubMed    


    May 2021
  21. SAYGIN C, Hu E, Zhang P, Sher S, et al
    Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
    Leukemia. 2021 May 21. pii: 10.1038/s41375-021-01295.
    PubMed     Abstract available


  22. VAN DER ZWET JCG, Buijs-Gladdines JGCAM, Cordo' V, Debets DO, et al
    MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
    Leukemia. 2021 May 18. pii: 10.1038/s41375-021-01291.
    PubMed     Abstract available


  23. JAIN N, Thompson P, Burger J, Ferrajoli A, et al
    Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Leukemia. 2021 May 18. pii: 10.1038/s41375-021-01280.
    PubMed     Abstract available


  24. BRECCIA M, Pregno P, Castagnetti F, Bonifacio M, et al
    Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01292.
    PubMed    


  25. CARRATT SA, Braun TP, Coblentz C, Schonrock Z, et al
    Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01278.
    PubMed     Abstract available


  26. DOURTHE ME, Rabian F, Yakouben K, Chevillon F, et al
    Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01281.
    PubMed     Abstract available


  27. VAN DER WERF I, Wojtuszkiewicz A, Yao H, Sciarrillo R, et al
    SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01273.
    PubMed    


  28. ROEKER LE, Knorr DA, Thompson MC, Nivar M, et al
    COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
    Leukemia. 2021 May 13. pii: 10.1038/s41375-021-01270.
    PubMed    


  29. HUGHES TP, Clementino NCD, Fominykh M, Lipton JH, et al
    Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
    Leukemia. 2021 May 12. pii: 10.1038/s41375-021-01260.
    PubMed     Abstract available


  30. YAMAGATA K, Shino M, Aikawa Y, Fujita S, et al
    Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
    Leukemia. 2021 May 9. pii: 10.1038/s41375-021-01244.
    PubMed     Abstract available


  31. BRAVO-NAVAS S, Yanez L, Romon I, Briz M, et al
    Map of ubiquitin-like post-translational modifications in chronic lymphocytic leukemia. Role of p53 lysine 120 NEDDylation.
    Leukemia. 2021 May 8. pii: 10.1038/s41375-021-01184.
    PubMed    


  32. STOMPER J, Rotondo JC, Greve G, Lubbert M, et al
    Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
    Leukemia. 2021 May 6. pii: 10.1038/s41375-021-01218.
    PubMed     Abstract available


  33. DAVER N, Alotaibi AS, Bucklein V, Subklewe M, et al
    T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
    Leukemia. 2021 May 5. pii: 10.1038/s41375-021-01253.
    PubMed     Abstract available


  34. GREVER M, Andritsos L, Banerji V, Barrientos JC, et al
    Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
    Leukemia. 2021 May 4. pii: 10.1038/s41375-021-01257.
    PubMed     Abstract available


  35. HARRISON CJ
    Prevention of childhood leukaemia by lifestyle changes.
    Leukemia. 2021;35:1265-1266.
    PubMed    


  36. GREAVES M, Cazzaniga V, Ford A
    Can we prevent childhood Leukaemia?
    Leukemia. 2021;35:1258-1264.
    PubMed    


  37. BERG JL, Perfler B, Hatzl S, Uhl B, et al
    EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity.
    Leukemia. 2021;35:1521-1526.
    PubMed    


  38. LARGEAUD L, Cornillet-Lefebvre P, Hamel JF, Dumas PY, et al
    Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
    Leukemia. 2021;35:1291-1300.
    PubMed     Abstract available


    April 2021
  39. KIEHLMEIER S, Rafiee MR, Bakr A, Mika J, et al
    Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Leukemia. 2021 Apr 28. pii: 10.1038/s41375-021-01235.
    PubMed     Abstract available


  40. BHM JW, Sia KCS, Jones C, Evans K, et al
    Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
    Leukemia. 2021 Apr 24. pii: 10.1038/s41375-021-01248.
    PubMed     Abstract available


  41. GUNNARSSON R, Yang M, Olsson-Arvidsson L, Biloglav A, et al
    Single base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing.
    Leukemia. 2021 Apr 16. pii: 10.1038/s41375-021-01242.
    PubMed    


  42. BROWN PA, Kairalla JA, Hilden JM, Dreyer ZE, et al
    Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01245.
    PubMed    


  43. CARRENO-TARRAGONA G, Varghese LN, Sebastian E, Galvez E, et al
    A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01239.
    PubMed    


  44. MONTALBAN-BRAVO G, Hammond D, DiNardo CD, Konopleva M, et al
    Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01240.
    PubMed    


  45. HSIEH YC, Kirschner K, Copland M
    Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01238.
    PubMed     Abstract available


  46. TAMBARO FP, Singh H, Jones E, Rytting M, et al
    Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01232.
    PubMed    


  47. SCHLEISS C, Carapito R, Fornecker LM, Muller L, et al
    Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01221.
    PubMed     Abstract available


  48. BATTA K, Bossenbroek HM, Pemmaraju N, Wilks DP, et al
    Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01228.
    PubMed    


  49. HU GH, Zhao XY, Zuo YX, Chang YJ, et al
    Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
    Leukemia. 2021 Apr 6. pii: 10.1038/s41375-021-01236.
    PubMed     Abstract available


  50. MILLER CR, Huang Y, Ruppert AS, Labanowska J, et al
    Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
    Leukemia. 2021 Apr 5. pii: 10.1038/s41375-021-01237.
    PubMed    


  51. DAVIDS MS, Fisher DC, Tyekucheva S, McDonough M, et al
    A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
    Leukemia. 2021;35:1064-1072.
    PubMed     Abstract available


  52. REEDIJK AMJ, Coebergh JWW, de Groot-Kruseman HA, van der Sluis IM, et al
    Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015.
    Leukemia. 2021;35:1001-1011.
    PubMed     Abstract available


  53. LONTOS K, Yabes JG, Farah RJ, Boyiadzis M, et al
    Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma.
    Leukemia. 2021;35:1193-1196.
    PubMed    


  54. AU YZ, Gu M, De Braekeleer E, Gozdecka M, et al
    KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.
    Leukemia. 2021;35:1012-1022.
    PubMed     Abstract available


    March 2021
  55. EISENWORT G, Sadovnik I, Keller A, Ivanov D, et al
    Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
    Leukemia. 2021 Mar 30. pii: 10.1038/s41375-021-01227.
    PubMed     Abstract available


  56. WIEDUWILT MJ, Stock W, Advani A, Luger S, et al
    Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from
    Leukemia. 2021 Mar 30. pii: 10.1038/s41375-021-01213.
    PubMed     Abstract available


  57. DHAKAL B, Patel S, Girnius S, Bachegowda L, et al
    Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
    Leukemia. 2021 Mar 29. pii: 10.1038/s41375-021-01233.
    PubMed    


  58. GRANDITS AM, Nguyen CH, Schlerka A, Hackl H, et al
    Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
    Leukemia. 2021 Mar 29. pii: 10.1038/s41375-021-01224.
    PubMed     Abstract available


  59. DINARDO CD, Stein EM, Pigneux A, Altman JK, et al
    Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
    Leukemia. 2021 Mar 26. pii: 10.1038/s41375-021-01229.
    PubMed    


  60. WALTER RB, Ofran Y, Wierzbowska A, Ravandi F, et al
    Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
    Leukemia. 2021 Mar 23. pii: 10.1038/s41375-021-01230.
    PubMed     Abstract available


  61. RIVAS JR, Liu Y, Alhakeem SS, Eckenrode JM, et al
    Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Leukemia. 2021 Mar 17. pii: 10.1038/s41375-021-01217.
    PubMed     Abstract available


  62. LLAO-CID L, Roessner PM, Chapaprieta V, Ozturk S, et al
    EOMES is essential for antitumor activity of CD8(+) T cells in chronic lymphocytic leukemia.
    Leukemia. 2021 Mar 17. pii: 10.1038/s41375-021-01198.
    PubMed     Abstract available


  63. TIACCI E, De Carolis L, Simonetti E, Merluzzi M, et al
    Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.
    Leukemia. 2021 Mar 17. pii: 10.1038/s41375-021-01210.
    PubMed    


  64. DIEDRICH JD, Dong Q, Ferguson DC, Bergeron BP, et al
    Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.
    Leukemia. 2021 Mar 13. pii: 10.1038/s41375-021-01209.
    PubMed     Abstract available


  65. STANULLA M, Schaeffeler E, Moricke A, Buchmann S, et al
    Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia.
    Leukemia. 2021 Mar 13. pii: 10.1038/s41375-021-01203.
    PubMed     Abstract available


  66. CHAN O, Renneville A, Padron E
    Chronic myelomonocytic leukemia diagnosis and management.
    Leukemia. 2021 Mar 13. pii: 10.1038/s41375-021-01207.
    PubMed     Abstract available


  67. HE X, Feng Z, Ma J, Zhang X, et al
    CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch.
    Leukemia. 2021 Mar 12. pii: 10.1038/s41375-021-01208.
    PubMed    


  68. RADICH JP, Hochhaus A, Masszi T, Hellmann A, et al
    Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
    Leukemia. 2021 Mar 11. pii: 10.1038/s41375-021-01205.
    PubMed     Abstract available


  69. PERICA K, Flynn J, Curran KJ, Rivere I, et al
    Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
    Leukemia. 2021 Mar 8. pii: 10.1038/s41375-021-01196.
    PubMed    


  70. YAMATO G, Deguchi T, Terui K, Toki T, et al
    Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome.
    Leukemia. 2021 Mar 3. pii: 10.1038/s41375-021-01171.
    PubMed    


  71. KAZIANKA L, Staber PB
    Blood cancer driver Musashi-2 as therapeutic target in chronic lymphocytic leukemia.
    Leukemia. 2021 Mar 2. pii: 10.1038/s41375-021-01144.
    PubMed    


  72. LARSON RA, Mandrekar SJ, Huebner LJ, Sanford BL, et al
    Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
    Leukemia. 2021 Mar 2. pii: 10.1038/s41375-021-01179.
    PubMed     Abstract available


  73. BOND J, Krzywon A, Lhermitte L, Roumier C, et al
    A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis.
    Leukemia. 2021;35:724-736.
    PubMed     Abstract available


  74. YOU X, Chang YI, Kong G, Ranheim EA, et al
    Gata2 -77 enhancer regulates adult hematopoietic stem cell survival.
    Leukemia. 2021;35:901-905.
    PubMed    


  75. DE-MORGAN A, Meggendorfer M, Haferlach C, Shlush L, et al
    Male predominance in AML is associated with specific preleukemic mutations.
    Leukemia. 2021;35:867-870.
    PubMed    


  76. WASS M, Gollner S, Besenbeck B, Schlenk RF, et al
    A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
    Leukemia. 2021;35:701-711.
    PubMed     Abstract available


    February 2021
  77. KOVALOVSKY D, Yoon JH, Cyr MG, Simon S, et al
    Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
    Leukemia. 2021 Feb 25. pii: 10.1038/s41375-021-01188.
    PubMed     Abstract available


  78. BROWN PA, Kairalla JA, Hilden JM, Dreyer ZE, et al
    FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
    Leukemia. 2021 Feb 23. pii: 10.1038/s41375-021-01177.
    PubMed     Abstract available


  79. MAFFEI R, Fiorcari S, Benatti S, Atene CG, et al
    IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK.
    Leukemia. 2021 Feb 23. pii: 10.1038/s41375-021-01178.
    PubMed     Abstract available


  80. VAN DER VELDEN VHJ, Bruggemann M, Cazzaniga G, Scheijen B, et al
    Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study.
    Leukemia. 2021 Feb 19. pii: 10.1038/s41375-021-01154.
    PubMed    


  81. ECTOR GICG, Visser O, Posthuma EFM, Westerweel PE, et al
    Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands.
    Leukemia. 2021 Feb 18. pii: 10.1038/s41375-021-01174.
    PubMed    


  82. ROTBAIN EC, Niemann CU, Rostgaard K, da Cunha-Bang C, et al
    Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death.
    Leukemia. 2021 Feb 18. pii: 10.1038/s41375-021-01156.
    PubMed     Abstract available


  83. TAGA T, Tanaka S, Hasegawa D, Terui K, et al
    Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
    Leukemia. 2021 Feb 15. pii: 10.1038/s41375-021-01157.
    PubMed     Abstract available


  84. CUCCHI DGJ, Polak TB, Ossenkoppele GJ, Uyl-De Groot CA, et al
    Two decades of targeted therapies in acute myeloid leukemia.
    Leukemia. 2021 Feb 15. pii: 10.1038/s41375-021-01164.
    PubMed     Abstract available


  85. NGUYEN LXT, Zhang B, Hoang DH, Zhao D, et al
    Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
    Leukemia. 2021 Feb 15. pii: 10.1038/s41375-021-01166.
    PubMed     Abstract available


  86. RAPAPORT F, Neelamraju Y, Baslan T, Hassane D, et al
    Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
    Leukemia. 2021 Feb 12. pii: 10.1038/s41375-021-01153.
    PubMed    


  87. CHUN S, Kim HY, Kim HJ, Koo HH, et al
    Low CtBP2 expression is associated with a stem cell-like signature and adverse clinical outcome in childhood B-cell lymphoblastic leukemia.
    Leukemia. 2021 Feb 12. pii: 10.1038/s41375-021-01151.
    PubMed    


  88. WINTER G, Kirschner-Schwabe R, Groeneveld-Krentz S, Escherich G, et al
    Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome.
    Leukemia. 2021 Feb 12. pii: 10.1038/s41375-021-01163.
    PubMed    


  89. DEL GALY AS, Marouf A, Raffoux E, Robin M, et al
    Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.
    Leukemia. 2021 Feb 9. pii: 10.1038/s41375-020-01112.
    PubMed    


  90. PATKAR N, Kakirde C, Shaikh AF, Salve R, et al
    Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
    Leukemia. 2021 Feb 8. pii: 10.1038/s41375-021-01131.
    PubMed     Abstract available


  91. LIBBRECHT C, Xie HM, Kingsley MC, Haladyna JN, et al
    Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
    Leukemia. 2021 Feb 4. pii: 10.1038/s41375-021-01146.
    PubMed     Abstract available


  92. ESTEVE J, Giebel S, Labopin M, Czerw T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An anal
    Leukemia. 2021 Feb 4. pii: 10.1038/s41375-021-01135.
    PubMed     Abstract available


  93. BAUMANN T, Moia R, Gaidano G, Delgado J, et al
    Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.
    Leukemia. 2021 Feb 4. pii: 10.1038/s41375-021-01149.
    PubMed     Abstract available


  94. WEI AH, Ribera JM, Larson RA, Ritchie D, et al
    Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia.
    Leukemia. 2021 Feb 4. pii: 10.1038/s41375-020-01089.
    PubMed     Abstract available


  95. GE Z, Song C, Ding Y, Tan BH, et al
    Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
    Leukemia. 2021 Feb 2. pii: 10.1038/s41375-021-01132.
    PubMed     Abstract available


  96. ROESSNER PM, Llao Cid L, Lupar E, Roider T, et al
    EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4(+) T cells in chronic lymphocytic leukemia.
    Leukemia. 2021 Feb 1. pii: 10.1038/s41375-021-01136.
    PubMed     Abstract available


  97. PAIVA B, Vidriales MB, Sempere A, Tarin F, et al
    Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
    Leukemia. 2021 Feb 1. pii: 10.1038/s41375-021-01126.
    PubMed     Abstract available


  98. GANESAN R, Chennupati V, Ramachandran B, Hansen MR, et al
    Selective recruitment of gammadelta T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
    Leukemia. 2021 Feb 1. pii: 10.1038/s41375-021-01122.
    PubMed     Abstract available


  99. NAIR R, Salinas-Illarena A, Baldauf HM
    New strategies to treat AML: novel insights into AML survival pathways and combination therapies.
    Leukemia. 2021;35:299-311.
    PubMed     Abstract available


  100. YANG S, Varghese AM, Sood N, Chiattone C, et al
    Ethnic and geographic diversity of chronic lymphocytic leukaemia.
    Leukemia. 2021;35:433-439.
    PubMed     Abstract available


  101. LE Q, Hadland B, Meshinchi S, Bernstein I, et al
    Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment.
    Leukemia. 2021;35:601-605.
    PubMed    


  102. ZHAO J, Sui P, Wu B, Chen A, et al
    Benzene induces rapid leukemic transformation after prolonged hematotoxicity in a murine model.
    Leukemia. 2021;35:595-600.
    PubMed    


  103. GHASEMI R, Struthers H, Wilson ER, Spencer DH, et al
    Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.
    Leukemia. 2021;35:404-416.
    PubMed     Abstract available


    January 2021
  104. PALACIOS F, Yan XJ, Ferrer G, Chen SS, et al
    Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.
    Leukemia. 2021 Jan 27. pii: 10.1038/s41375-020-01115.
    PubMed     Abstract available


  105. BHATT NS, Baassiri MJ, Liu W, Bhakta N, et al
    Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study.
    Leukemia. 2021 Jan 25. pii: 10.1038/s41375-021-01134.
    PubMed     Abstract available


  106. YI S, Yan Y, Jin M, Xiong W, et al
    High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia.
    Leukemia. 2021 Jan 22. pii: 10.1038/s41375-021-01124.
    PubMed    


  107. GOEMANS BF, Noort S, Blink M, Wang YD, et al
    Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia.
    Leukemia. 2021 Jan 22. pii: 10.1038/s41375-021-01128.
    PubMed    


  108. BENMEBAREK MR, Cadilha BL, Herrmann M, Lesch S, et al
    A modular and controllable T cell therapy platform for acute myeloid leukemia.
    Leukemia. 2021 Jan 7. pii: 10.1038/s41375-020-01109.
    PubMed     Abstract available


  109. KANTARJIAN HM, Hughes TP, Larson RA, Kim DW, et al
    Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
    Leukemia. 2021 Jan 7. pii: 10.1038/s41375-020-01111.
    PubMed     Abstract available


  110. O'NIONS J, Muir L, Zheng J, Rees-Spear C, et al
    SARS-CoV-2 antibody responses in patients with acute leukaemia.
    Leukemia. 2021;35:289-292.
    PubMed    


  111. SWOBODA DM, Ali NA, Chan O, Padron E, et al
    PTPN11 mutations are associated with poor outcomes across myeloid malignancies.
    Leukemia. 2021;35:286-288.
    PubMed    


  112. NOFRINI V, Matteucci C, Pellanera F, Gorello P, et al
    Activating somatic and germline TERT promoter variants in myeloid malignancies.
    Leukemia. 2021;35:274-278.
    PubMed    


  113. NAGATE Y, Ezoe S, Fujita J, Okuzaki D, et al
    Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.
    Leukemia. 2021;35:107-118.
    PubMed     Abstract available


    December 2020
  114. WALTER RB, Appelbaum FR, Estey EH
    Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.
    Leukemia. 2020 Dec 16. pii: 10.1038/s41375-020-01110.
    PubMed    


  115. TIRADO-GONZALEZ I, Czlonka E, Nevmerzhitskaya A, Soetopo D, et al
    Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.
    Leukemia. 2020 Dec 1. pii: 10.1038/s41375-020-01071.
    PubMed     Abstract available


  116. DE BARRIOS O, Galaras A, Trincado JL, Azagra A, et al
    HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia.
    Leukemia. 2020 Dec 1. pii: 10.1038/s41375-020-01097.
    PubMed    


  117. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS.
    Leukemia. 2020 Dec 1. pii: 10.1038/s41375-020-01098.
    PubMed    


  118. VU TT, Stolzel F, Wang KW, Rollig C, et al
    miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
    Leukemia. 2020 Dec 1. pii: 10.1038/s41375-020-01095.
    PubMed     Abstract available


  119. BOND DA, Huang Y, Fisher JL, Ruppert AS, et al
    Second cancer incidence in CLL patients receiving BTK inhibitors.
    Leukemia. 2020;34:3197-3205.
    PubMed     Abstract available


  120. PAN J, Tan Y, Deng B, Tong C, et al
    Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children.
    Leukemia. 2020;34:3382-3387.
    PubMed    


  121. DUN MD, Mannan A, Rigby CJ, Butler S, et al
    Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.
    Leukemia. 2020;34:3393-3397.
    PubMed    


    November 2020
  122. EMADI A, Kapadia B, Bollino D, Bhandary B, et al
    Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
    Leukemia. 2020 Nov 16. pii: 10.1038/s41375-020-01080.
    PubMed     Abstract available


  123. ESTEY E
    New treatments for acute myeloid leukemia: how much has changed?
    Leukemia. 2020 Nov 12. pii: 10.1038/s41375-020-01084.
    PubMed    


  124. ADNAN-AWAD S, Kim D, Hohtari H, Javarappa KK, et al
    Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.
    Leukemia. 2020 Nov 9. pii: 10.1038/s41375-020-01082.
    PubMed     Abstract available


  125. SPORTOLETTI P, Sorcini D, Guzman AG, Reyes JM, et al
    Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice.
    Leukemia. 2020 Nov 6. pii: 10.1038/s41375-020-01075.
    PubMed     Abstract available


  126. ELCHEVA IA, Spiegelman VS
    Targeting RNA-binding proteins in acute and chronic leukemia.
    Leukemia. 2020 Nov 4. pii: 10.1038/s41375-020-01066.
    PubMed     Abstract available


  127. KOMROKJI RS, Ali NA, Sallman D, Padron E, et al
    Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL).
    Leukemia. 2020;34:3097-3099.
    PubMed    


  128. ZHAO H, Deininger MW
    Declaration of Bcr-Abl1 independence.
    Leukemia. 2020;34:2827-2836.
    PubMed    


  129. HEUSER M, Palmisiano N, Mantzaris I, Mims A, et al
    Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
    Leukemia. 2020;34:2903-2913.
    PubMed     Abstract available


  130. VENKATARAMAN V, Casey KS, Onozato M, Cin PD, et al
    Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy.
    Leukemia. 2020;34:3050-3054.
    PubMed    


  131. LIBERT D, Yuan CM, Masih KE, Galera P, et al
    Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.
    Leukemia. 2020;34:3064-3069.
    PubMed    


    October 2020
  132. CAPO-CHICHI JM, Kagotho E, Nayyar R, Zhao D, et al
    Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KIT(D816V) and FLT3-ITD.
    Leukemia. 2020 Oct 26. pii: 10.1038/s41375-020-01073.
    PubMed    


  133. PUTZER S, Varghese L, von Jan J, Braun T, et al
    Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.
    Leukemia. 2020 Oct 23. pii: 10.1038/s41375-020-01067.
    PubMed     Abstract available


  134. HASAN MK, Ghia EM, Rassenti LZ, Widhopf GF 2nd, et al
    Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
    Leukemia. 2020 Oct 23. pii: 10.1038/s41375-020-01055.
    PubMed     Abstract available


  135. SIVINA M, Xiao L, Kim E, Vaca A, et al
    CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
    Leukemia. 2020 Oct 21. pii: 10.1038/s41375-020-01063.
    PubMed     Abstract available


  136. BARNEA SLONIM L, Gao J, Burkart M, Odetola OE, et al
    Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.
    Leukemia. 2020 Oct 21. pii: 10.1038/s41375-020-01061.
    PubMed    


  137. BRECCIA M, Piciocchi A, De Stefano V, Finazzi G, et al
    COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey.
    Leukemia. 2020;34:2813-2814.
    PubMed    


  138. LAI P, Chen X, Qin L, Jiang Z, et al
    The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection.
    Leukemia. 2020;34:2790-2793.
    PubMed    


  139. WANG Y, Liu Y, Tan X, Pan B, et al
    Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.
    Leukemia. 2020;34:2704-2707.
    PubMed     Abstract available


  140. MYBURGH R, Kiefer JD, Russkamp NF, Magnani CF, et al
    Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
    Leukemia. 2020;34:2688-2703.
    PubMed     Abstract available


    September 2020
  141. ECTOR GICG, Visser O, Westerweel PE, Janssen JJWM, et al
    Correction: Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017.
    Leukemia. 2020 Sep 28. pii: 10.1038/s41375-020-01040.
    PubMed     Abstract available


  142. KATTIH B, Shirvani A, Klement P, Garrido AM, et al
    IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis.
    Leukemia. 2020 Sep 18. pii: 10.1038/s41375-020-01043.
    PubMed     Abstract available


  143. LETESTU R, Dahmani A, Boubaya M, Baseggio L, et al
    Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
    Leukemia. 2020 Sep 15. pii: 10.1038/s41375-020-01009.
    PubMed     Abstract available


  144. JUNCO JJ, Chen T, Rashid R, Terrell M, et al
    An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance.
    Leukemia. 2020 Sep 11. pii: 10.1038/s41375-020-01036.
    PubMed    


  145. REDA G, Noto A, Cassin R, Zamprogna G, et al
    Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL).
    Leukemia. 2020;34:2531-2532.
    PubMed    


  146. ECTOR GICG, Huijskens EGW, Blijlevens NMA, Westerweel PE, et al
    Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study.
    Leukemia. 2020;34:2533-2535.
    PubMed    


  147. QIU Y, Huang S
    CTCF-mediated genome organization and leukemogenesis.
    Leukemia. 2020;34:2295-2304.
    PubMed     Abstract available


  148. KAYSER S, Rahme R, Martinez-Cuadron D, Ghiaur G, et al
    Outcome of older (>/=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.
    Leukemia. 2020;34:2333-2341.
    PubMed     Abstract available


    August 2020
  149. ROEKER LE, Knorr DA, Pessin MS, Ramanathan LV, et al
    Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.
    Leukemia. 2020 Aug 27. pii: 10.1038/s41375-020-01030.
    PubMed    


  150. VON WENSERSKI L, Schultheiss C, Bolz S, Schliffke S, et al
    SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.
    Leukemia. 2020 Aug 21. pii: 10.1038/s41375-020-01025.
    PubMed     Abstract available


  151. ADNAN AWAD S, Dufva O, Ianevski A, Ghimire B, et al
    RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
    Leukemia. 2020 Aug 11. pii: 10.1038/s41375-020-01011.
    PubMed     Abstract available


  152. MIMS AS, Kohlschmidt J, Eisfeld AK, Mromicronzek K, et al
    Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations.
    Leukemia. 2020 Aug 5. pii: 10.1038/s41375-020-1007.
    PubMed    


  153. FURSTENAU M, Langerbeins P, De Silva N, Fink AM, et al
    COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
    Leukemia. 2020;34:2225-2229.
    PubMed    


  154. MACHOVA POLAKOVA K, Zizkova H, Zuna J, Motlova E, et al
    Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
    Leukemia. 2020;34:2113-2124.
    PubMed     Abstract available


  155. HEHLMANN R, Voskanyan A, Lauseker M, Pfirrmann M, et al
    High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
    Leukemia. 2020;34:2074-2086.
    PubMed     Abstract available


  156. KAISER A, Schmidt M, Huber O, Frietsch JJ, et al
    SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders.
    Leukemia. 2020;34:2206-2216.
    PubMed     Abstract available


    July 2020
  157. AUMANN WK, Heath JL, Conway AE, Sze SK, et al
    Fusion of the CRM1 nuclear export receptor to AF10 causes leukemia and transcriptional activation of HOXA genes.
    Leukemia. 2020 Jul 30. pii: 10.1038/s41375-020-0998.
    PubMed    


  158. DEL GALY AS, Marouf A, Raffoux E, Robin M, et al
    Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.
    Leukemia. 2020 Jul 30. pii: 10.1038/s41375-020-1004.
    PubMed    


  159. TOSELLO V, Bongiovanni D, Liu J, Pan Q, et al
    Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination.
    Leukemia. 2020 Jul 30. pii: 10.1038/s41375-020-0999.
    PubMed     Abstract available


  160. GASSNER FJ, Zaborsky N, Buchumenski I, Levanon EY, et al
    RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia.
    Leukemia. 2020 Jul 30. pii: 10.1038/s41375-020-0995.
    PubMed     Abstract available


  161. YUN S, Geyer SM, Komrokji RS, Al Ali NH, et al
    Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).
    Leukemia. 2020 Jul 29. pii: 10.1038/s41375-020-0997.
    PubMed     Abstract available


  162. ANDERSEN MA, Moser CE, Lundgren J, Niemann CU, et al
    Correction: Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
    Leukemia. 2020 Jul 27. pii: 10.1038/s41375-020-0992.
    PubMed     Abstract available


  163. FANG C, Rao S, Crispino JD, Ntziachristos P, et al
    Determinants and role of chromatin organization in acute leukemia.
    Leukemia. 2020 Jul 20. pii: 10.1038/s41375-020-0981.
    PubMed     Abstract available


  164. PARTING O, Langer S, Kuepper MK, Wessling C, et al
    Therapeutic inhibition of FcgammaRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
    Leukemia. 2020 Jul 20. pii: 10.1038/s41375-020-0977.
    PubMed     Abstract available


  165. ANDERSEN MA, Rostgaard K, Niemann CU, Hjalgrim H, et al
    Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study.
    Leukemia. 2020 Jul 20. pii: 10.1038/s41375-020-0980.
    PubMed     Abstract available


  166. JESTIN M, Tarfi S, Duchmann M, Badaoui B, et al
    Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study.
    Leukemia. 2020 Jul 20. pii: 10.1038/s41375-020-0955.
    PubMed    


  167. MALANI D, Yadav B, Kumar A, Potdar S, et al
    KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.
    Leukemia. 2020 Jul 17. pii: 10.1038/s41375-020-0978.
    PubMed    


  168. GRUBER E, Franich RL, Shortt J, Johnstone RW, et al
    Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia.
    Leukemia. 2020 Jul 13. pii: 10.1038/s41375-020-0973.
    PubMed    


  169. BROWN JR, Zelenetz A, Furman R, Lamanna N, et al
    Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.
    Leukemia. 2020 Jul 12. pii: 10.1038/s41375-020-0974.
    PubMed    


  170. TAMBE M, Karjalainen E, Vaha-Koskela M, Bulanova D, et al
    Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.
    Leukemia. 2020 Jul 10. pii: 10.1038/s41375-020-0972.
    PubMed     Abstract available


  171. SCARFO L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, et al
    COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
    Leukemia. 2020 Jul 9. pii: 10.1038/s41375-020-0959.
    PubMed     Abstract available


  172. ABECASIS M, Cross NCP, Brito M, Ferreira I, et al
    Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia.
    Leukemia. 2020 Jul 6. pii: 10.1038/s41375-020-0957.
    PubMed     Abstract available


  173. OSTERGAARD A, Bohnstedt C, Grell K, Degn M, et al
    Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy.
    Leukemia. 2020 Jul 4. pii: 10.1038/s41375-020-0946.
    PubMed    


  174. BAUMANN T, Delgado J, Montserrat E
    CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
    Leukemia. 2020;34:1954-1956.
    PubMed    


  175. LI W, Wang D, Guo J, Yuan G, et al
    COVID-19 in persons with chronic myeloid leukaemia.
    Leukemia. 2020;34:1799-1804.
    PubMed     Abstract available


  176. REISSER T, Halbgebauer D, Scheurer J, Wolf L, et al
    In vitro-generated alloantigen-specific Th9 cells mediate antileukemia cytotoxicity in the absence of graft-versus-host disease.
    Leukemia. 2020;34:1943-1948.
    PubMed    


  177. OSSENKOPPELE GJ, Breems DA, Stuessi G, van Norden Y, et al
    Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
    Leukemia. 2020;34:1751-1759.
    PubMed     Abstract available


  178. BLAKEMORE SJ, Clifford R, Parker H, Antoniou P, et al
    Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
    Leukemia. 2020;34:1760-1774.
    PubMed     Abstract available


  179. KIM R, Boissel N, Touzart A, Leguay T, et al
    Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.
    Leukemia. 2020;34:1730-1740.
    PubMed     Abstract available


  180. GERNER RR, Macheiner S, Reider S, Siegmund K, et al
    Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.
    Leukemia. 2020;34:1885-1897.
    PubMed     Abstract available


  181. HORNE GA, Stobo J, Kelly C, Mukhopadhyay A, et al
    A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
    Leukemia. 2020;34:1775-1786.
    PubMed     Abstract available


    June 2020
  182. GARCIA EG, Veloso A, Oliveira ML, Allen JR, et al
    PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.
    Leukemia. 2020 Jun 30. pii: 10.1038/s41375-020-0937.
    PubMed     Abstract available


  183. PFIRRMANN M, Clark RE, Prejzner W, Lauseker M, et al
    The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
    Leukemia. 2020 Jun 29. pii: 10.1038/s41375-020-0931.
    PubMed     Abstract available


  184. JENSEN P, Carlet M, Schlenk RF, Weber A, et al
    Requirement for LIM kinases in acute myeloid leukemia.
    Leukemia. 2020 Jun 26. pii: 10.1038/s41375-020-0943.
    PubMed     Abstract available


  185. LOONTIENS S, Vanhauwaert S, Depestel L, Dewyn G, et al
    A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models.
    Leukemia. 2020 Jun 26. pii: 10.1038/s41375-020-0938.
    PubMed    


  186. CERRANO M, Duchmann M, Kim R, Vasseur L, et al
    Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.
    Leukemia. 2020 Jun 24. pii: 10.1038/s41375-020-0932.
    PubMed     Abstract available


  187. KLOOS A, Mintzas K, Winckler L, Gabdoulline R, et al
    Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
    Leukemia. 2020 Jun 24. pii: 10.1038/s41375-020-0929.
    PubMed     Abstract available


  188. HOCHHAUS A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, et al
    Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
    Leukemia. 2020 Jun 22. pii: 10.1038/s41375-020-0915.
    PubMed     Abstract available


  189. MOLICA S, Giannarelli D
    Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis.
    Leukemia. 2020 Jun 21. pii: 10.1038/s41375-020-0924.
    PubMed    


  190. FERRARA F, Zappasodi P, Roncoroni E, Borlenghi E, et al
    Impact of Covid-19 on the treatment of acute myeloid leukemia.
    Leukemia. 2020 Jun 19. pii: 10.1038/s41375-020-0925.
    PubMed    


  191. DAVI F, Langerak AW, de Septenville AL, Kolijn PM, et al
    Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing.
    Leukemia. 2020 Jun 19. pii: 10.1038/s41375-020-0923.
    PubMed     Abstract available


  192. ALFAYEZ M, Issa GC, Patel KP, Wang F, et al
    The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
    Leukemia. 2020 Jun 19. pii: 10.1038/s41375-020-0920.
    PubMed     Abstract available


  193. BRECCIA M, Abruzzese E, Bocchia M, Bonifacio M, et al
    Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.
    Leukemia. 2020 Jun 18. pii: 10.1038/s41375-020-0904.
    PubMed    


  194. HAUER J, Fischer U, Auer F, Borkhardt A, et al
    Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.
    Leukemia. 2020 Jun 18. pii: 10.1038/s41375-020-0871.
    PubMed    


  195. MARCAIS A, Lhermitte L, Artesi M, Laurent C, et al
    Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype.
    Leukemia. 2020 Jun 17. pii: 10.1038/s41375-020-0900.
    PubMed     Abstract available


  196. MAURO FR, Giannarelli D, Galluzzo CM, Vitale C, et al
    Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).
    Leukemia. 2020 Jun 17. pii: 10.1038/s41375-020-0884.
    PubMed     Abstract available


  197. ISSA GC, Kantarjian HM, Xiao L, Ning J, et al
    Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
    Leukemia. 2020 Jun 16. pii: 10.1038/s41375-020-0916.
    PubMed     Abstract available


  198. POPOV A, Buldini B, De Lorenzo P, Disaro S, et al
    Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols.
    Leukemia. 2020 Jun 12. pii: 10.1038/s41375-020-0912.
    PubMed    


  199. WONG RL, Ketcham M, Irwin T, Akilesh S, et al
    Donor-derived acute promyelocytic leukemia presenting as myeloid sarcoma in a transplanted kidney.
    Leukemia. 2020 Jun 10. pii: 10.1038/s41375-020-0903.
    PubMed    


  200. NORSWORTHY KJ, Avagyan A, Bird ST, Li Y, et al
    Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis.
    Leukemia. 2020 Jun 9. pii: 10.1038/s41375-020-0905.
    PubMed    


  201. ECTOR GICG, Visser O, Westerweel PE, Janssen JJWM, et al
    Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017.
    Leukemia. 2020 Jun 8. pii: 10.1038/s41375-020-0902.
    PubMed    


  202. YAN F, Wong NC, Powell DR, Curtis DJ, et al
    A 9-gene score for risk stratification in B-cell acute lymphoblastic leukemia.
    Leukemia. 2020 Jun 2. pii: 10.1038/s41375-020-0888.
    PubMed    


  203. WANDER P, Cheung LC, Pinhanos SS, Jones L, et al
    Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
    Leukemia. 2020 Jun 2. pii: 10.1038/s41375-020-0895.
    PubMed    


  204. MIMMI S, Maisano D, Nistico N, Vecchio E, et al
    Detection of chronic lymphocytic leukemia subpopulations in peripheral blood by phage ligands of tumor immunoglobulin B cell receptors.
    Leukemia. 2020 Jun 1. pii: 10.1038/s41375-020-0885.
    PubMed    


  205. QUIJADA-ALAMO M, Hernandez-Sanchez M, Alonso-Perez V, Rodriguez-Vicente AE, et al
    CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
    Leukemia. 2020;34:1599-1612.
    PubMed     Abstract available


  206. MORSINK LM, Othus M, Bezerra ED, Wood BL, et al
    Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.
    Leukemia. 2020;34:1577-1587.
    PubMed     Abstract available


  207. ZEIDNER JF, Knaus HA, Zeidan AM, Blackford AL, et al
    Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
    Leukemia. 2020;34:1563-1576.
    PubMed     Abstract available


  208. CAYE A, Rouault-Pierre K, Strullu M, Lainey E, et al
    Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.
    Leukemia. 2020;34:1658-1668.
    PubMed     Abstract available


    May 2020
  209. ZINNGREBE J, Debatin KM, Fischer-Posovszky P
    Adipocytes in hematopoiesis and acute leukemia: friends, enemies, or innocent bystanders?
    Leukemia. 2020 May 30. pii: 10.1038/s41375-020-0886.
    PubMed     Abstract available


  210. EISFELD AK, Kohlschmidt J, Mims A, Nicolet D, et al
    Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
    Leukemia. 2020 May 27. pii: 10.1038/s41375-020-0872.
    PubMed     Abstract available


  211. MIDIC D, Rinke J, Perner F, Muller V, et al
    Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders.
    Leukemia. 2020 May 26. pii: 10.1038/s41375-020-0869.
    PubMed     Abstract available


  212. SHARF G, Marin C, Bradley JA, Pemberton-Whiteley Z, et al
    Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs.
    Leukemia. 2020 May 26. pii: 10.1038/s41375-020-0867.
    PubMed     Abstract available


  213. ROESSNER PM, Seiffert M
    T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
    Leukemia. 2020 May 26. pii: 10.1038/s41375-020-0873.
    PubMed     Abstract available


  214. CARTEL M, Mouchel PL, Gotanegre M, David L, et al
    Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Leukemia. 2020 May 23. pii: 10.1038/s41375-020-0878.
    PubMed     Abstract available


  215. KUMAR R, Pereira RS, Zanetti C, Minciacchi VR, et al
    Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia.
    Leukemia. 2020 May 21. pii: 10.1038/s41375-020-0866.
    PubMed     Abstract available


  216. LAURENT AP, Kotecha RS, Malinge S
    Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.
    Leukemia. 2020 May 20. pii: 10.1038/s41375-020-0854.
    PubMed     Abstract available


  217. BAMEZAI S, Demir D, Pulikkottil AJ, Ciccarone F, et al
    TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.
    Leukemia. 2020 May 15. pii: 10.1038/s41375-020-0864.
    PubMed     Abstract available


  218. LORENTINO F, Labopin M, Ciceri F, Vago L, et al
    Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.
    Leukemia. 2020 May 14. pii: 10.1038/s41375-020-0863.
    PubMed     Abstract available


  219. LUKAS M, Velten B, Sellner L, Tomska K, et al
    Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies.
    Leukemia. 2020 May 13. pii: 10.1038/s41375-020-0846.
    PubMed     Abstract available


  220. YOUNG KH
    Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.
    Leukemia. 2020 May 12. pii: 10.1038/s41375-020-0861.
    PubMed    


  221. KARLSSON C, Akula MK, Staffas A, Cisowski J, et al
    Knockout of the RAS endoprotease RCE1 accelerates myeloid leukemia by downregulating GADD45b.
    Leukemia. 2020 May 12. pii: 10.1038/s41375-020-0859.
    PubMed    


  222. PARIKH SA, Gale RP, Kay NE
    Chronic lymphocytic leukemia in 2020: a surfeit of riches?
    Leukemia. 2020 May 11. pii: 10.1038/s41375-020-0852.
    PubMed    


  223. NAGLER A, Dholaria B, Labopin M, Savani BN, et al
    Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia.
    Leukemia. 2020 May 11. pii: 10.1038/s41375-020-0850.
    PubMed     Abstract available


  224. GARCIA-CANAVERAS JC, Lancho O, Ducker GS, Ghergurovich JM, et al
    SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia.
    Leukemia. 2020 May 7. pii: 10.1038/s41375-020-0845.
    PubMed     Abstract available


  225. HOCHHAUS A, Breccia M, Saglio G, Garcia-Gutierrez V, et al
    Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.
    Leukemia. 2020 May 4. pii: 10.1038/s41375-020-0842.
    PubMed     Abstract available


  226. JOSHI SK, Keck JM, Eide CA, Bottomly D, et al
    ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.
    Leukemia. 2020 May 4. pii: 10.1038/s41375-020-0844.
    PubMed    


  227. BAMOPOULOS SA, Batcha AMN, Jurinovic V, Rothenberg-Thurley M, et al
    Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
    Leukemia. 2020 May 1. pii: 10.1038/s41375-020-0839.
    PubMed     Abstract available


  228. REICH D, Kresinsky A, Muller JP, Bauer R, et al
    SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells.
    Leukemia. 2020;34:1444-1449.
    PubMed    


  229. DUPLOYEZ N, Goursaud L, Fenwarth L, Bories C, et al
    Familial myeloid malignancies with germline TET2 mutation.
    Leukemia. 2020;34:1450-1453.
    PubMed    


  230. DEB G, Wingelhofer B, Amaral FMR, Maiques-Diaz A, et al
    Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
    Leukemia. 2020;34:1266-1277.
    PubMed     Abstract available


  231. RODRIGUEZ S, Abundis C, Boccalatte F, Mehrotra P, et al
    Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL.
    Leukemia. 2020;34:1241-1252.
    PubMed     Abstract available


  232. SCHNEIDER E, Pochert N, Ruess C, MacPhee L, et al
    MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
    Leukemia. 2020;34:1253-1265.
    PubMed     Abstract available


    April 2020
  233. TOMLINSON CG, Sasa G, Aubert G, Martin-Giacalone B, et al
    Clinical and functional characterization of telomerase variants in patients with pediatric acute myeloid leukemia/myelodysplastic syndrome.
    Leukemia. 2020 Apr 21. pii: 10.1038/s41375-020-0835.
    PubMed    


  234. DHAKAL B, Patel S, Girnius S, Bachegowda L, et al
    Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
    Leukemia. 2020 Apr 20. pii: 10.1038/s41375-020-0830.
    PubMed     Abstract available


  235. WAKAMATSU M, Okuno Y, Murakami N, Miwata S, et al
    Detection of subclonal SETBP1 and JAK3 mutations in juvenile myelomonocytic leukemia using droplet digital PCR.
    Leukemia. 2020 Apr 20. pii: 10.1038/s41375-020-0817.
    PubMed    


  236. ELSAYED AH, Rafiee R, Cao X, Raimondi S, et al
    Correction: A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
    Leukemia. 2020 Apr 16. pii: 10.1038/s41375-020-0822.
    PubMed     Abstract available


  237. GENTILE M, Morabito F, Del Poeta G, Mauro FR, et al
    Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Leukemia. 2020 Apr 14. pii: 10.1038/s41375-020-0833.
    PubMed    


  238. THASTRUP M, Marquart HV, Levinsen M, Grell K, et al
    Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.
    Leukemia. 2020 Apr 8. pii: 10.1038/s41375-020-0821.
    PubMed     Abstract available


  239. CORTES JE, Jiang Q, Wang J, Weng J, et al
    Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.
    Leukemia. 2020 Apr 7. pii: 10.1038/s41375-020-0805.
    PubMed     Abstract available


  240. GODFREY L, Crump NT, O'Byrne S, Lau IJ, et al
    H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.
    Leukemia. 2020 Apr 2. pii: 10.1038/s41375-020-0808.
    PubMed     Abstract available


  241. RUZICKA M, Koenig LM, Formisano S, Boehmer DFR, et al
    RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
    Leukemia. 2020;34:1017-1026.
    PubMed     Abstract available


  242. WINICK N, Martin PL, Devidas M, Shuster J, et al
    Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.
    Leukemia. 2020;34:1006-1016.
    PubMed     Abstract available


  243. HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
    Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.
    Leukemia. 2020;34:1038-1051.
    PubMed     Abstract available


  244. FEDER K, Edmaier-Schroger K, Rawat VPS, Kirsten N, et al
    Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis.
    Leukemia. 2020;34:1027-1037.
    PubMed     Abstract available


  245. REN Z, Shrestha M, Sakamoto T, Melkman T, et al
    Opposing effects of NPM1wt and NPM1c mutants on AKT signaling in AML.
    Leukemia. 2020;34:1172-1176.
    PubMed    


  246. NAGLER A, Dholaria B, Labopin M, Socie G, et al
    The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
    Leukemia. 2020;34:1144-1153.
    PubMed     Abstract available


  247. KHAN HM, Gardner KM, Shaw C, Halpern AB, et al
    Need for routine examination of left ventricular ejection fraction in patients with AML.
    Leukemia. 2020;34:1169-1171.
    PubMed    


  248. ASNANI M, Hayer KE, Naqvi AS, Zheng S, et al
    Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.
    Leukemia. 2020;34:1202-1207.
    PubMed    


    March 2020
  249. HEROLD T, Rothenberg-Thurley M, Grunwald VV, Janke H, et al
    Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
    Leukemia. 2020 Mar 30. pii: 10.1038/s41375-020-0806.
    PubMed     Abstract available


  250. FOUSEK K, Watanabe J, Joseph SK, George A, et al
    CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
    Leukemia. 2020 Mar 24. pii: 10.1038/s41375-020-0792.
    PubMed     Abstract available


  251. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
    Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
    Leukemia. 2020 Mar 17. pii: 10.1038/s41375-020-0797.
    PubMed     Abstract available


  252. BEST S, Lam V, Liu T, Bruss N, et al
    Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
    Leukemia. 2020 Mar 16. pii: 10.1038/s41375-020-0794.
    PubMed     Abstract available


  253. MONTESINOS P, Roboz GJ, Bulabois CE, Subklewe M, et al
    Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
    Leukemia. 2020 Mar 16. pii: 10.1038/s41375-020-0773.
    PubMed     Abstract available


  254. BLAESCHKE F, Willier S, Stenger D, Lepenies M, et al
    Leukemia-induced dysfunctional TIM-3(+)CD4(+) bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients.
    Leukemia. 2020 Mar 13. pii: 10.1038/s41375-020-0793.
    PubMed     Abstract available


  255. ESKAZAN AE
    Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?
    Leukemia. 2020 Mar 13. pii: 10.1038/s41375-020-0796.
    PubMed    


  256. DIAZ-SANTA J, Rodriguez-Romanos R, Osca G, Pratcorona M, et al
    UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
    Leukemia. 2020 Mar 9. pii: 10.1038/s41375-020-0784.
    PubMed     Abstract available


  257. WEISBERG E, Meng C, Case A, Sattler M, et al
    Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
    Leukemia. 2020 Mar 6. pii: 10.1038/s41375-020-0782.
    PubMed     Abstract available


  258. STAHL M, Shallis RM, Wei W, Montesinos P, et al
    Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
    Leukemia. 2020 Mar 4. pii: 10.1038/s41375-020-0783.
    PubMed     Abstract available


  259. VENDITTI A, Peter Gale R, Buccisano F, Ossenkoppele G, et al
    Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?
    Leukemia. 2020 Mar 4. pii: 10.1038/s41375-020-0780.
    PubMed    


  260. ARINDRARTO W, Borras DM, de Groen RAL, van den Berg RR, et al
    Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing.
    Leukemia. 2020 Mar 3. pii: 10.1038/s41375-020-0762.
    PubMed     Abstract available


  261. HOCHHAUS A, Baccarani M, Silver RT, Schiffer C, et al
    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
    Leukemia. 2020 Mar 3. pii: 10.1038/s41375-020-0776.
    PubMed     Abstract available


  262. HORAK P, Uhrig S, Witzel M, Gil-Farina I, et al
    Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia.
    Leukemia. 2020 Mar 3. pii: 10.1038/s41375-020-0779.
    PubMed    


  263. MONTALBAN-BRAVO G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, et al
    Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes.
    Leukemia. 2020;34:872-881.
    PubMed     Abstract available


  264. TATSUMI G, Kawahara M, Yamamoto R, Hishizawa M, et al
    LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.
    Leukemia. 2020;34:746-758.
    PubMed     Abstract available


  265. BURGER JA, Barr PM, Robak T, Owen C, et al
    Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
    Leukemia. 2020;34:787-798.
    PubMed     Abstract available


  266. HERBRUEGGEN H, Mueller S, Rohde J, Arias Padilla L, et al
    Treatment and outcome of IG-MYC(+) neoplasms with precursor B-cell phenotype in childhood and adolescence.
    Leukemia. 2020;34:942-946.
    PubMed    


    February 2020
  267. WANG W, Beird H, Kroll CJ, Hu S, et al
    T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid.
    Leukemia. 2020 Feb 25. pii: 10.1038/s41375-020-0761.
    PubMed    


  268. BOSE P, Verstovsek S, Cortes JE, Tse S, et al
    A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.
    Leukemia. 2020 Feb 25. pii: 10.1038/s41375-020-0778.
    PubMed    


  269. LI Z, Jiang N, Lim EH, Chin WHN, et al
    Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq.
    Leukemia. 2020 Feb 25. pii: 10.1038/s41375-020-0774.
    PubMed     Abstract available


  270. PUTZER S, Varghese L, von Jan J, Braun T, et al
    Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.
    Leukemia. 2020 Feb 25. pii: 10.1038/s41375-020-0772.
    PubMed    


  271. EIDE CA, Kurtz SE, Kaempf A, Long N, et al
    Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
    Leukemia. 2020 Feb 24. pii: 10.1038/s41375-020-0764.
    PubMed     Abstract available


  272. LOCATELLI F, Whitlock JA, Peters C, Chen-Santel C, et al
    Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2020 Feb 24. pii: 10.1038/s41375-020-0770.
    PubMed    


  273. HU L, Ni F, Wang X, Fay ME, et al
    Decreased cell stiffness enhances leukemia development and progression.
    Leukemia. 2020 Feb 24. pii: 10.1038/s41375-020-0763.
    PubMed    


  274. XIA C, Wang T, Cheng H, Dong Y, et al
    Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment.
    Leukemia. 2020 Feb 24. pii: 10.1038/s41375-020-0775.
    PubMed     Abstract available


  275. ZHU S, Cheng X, Wang R, Tan Y, et al
    Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia.
    Leukemia. 2020 Feb 24. pii: 10.1038/s41375-020-0768.
    PubMed    


  276. SZENES E, Harzschel A, Decker S, Tissino E, et al
    TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia.
    Leukemia. 2020 Feb 21. pii: 10.1038/s41375-020-0759.
    PubMed    


  277. HUANG W, Liu B, Eklund EA
    Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia.
    Leukemia. 2020 Feb 20. pii: 10.1038/s41375-020-0771.
    PubMed     Abstract available


  278. TIAN XP, Xie D, Huang WJ, Ma SY, et al
    A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.
    Leukemia. 2020 Feb 20. pii: 10.1038/s41375-020-0757.
    PubMed     Abstract available


  279. THOMSON DW, Shahrin NH, Wang PPS, Wadham C, et al
    Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia.
    Leukemia. 2020 Feb 19. pii: 10.1038/s41375-020-0751.
    PubMed     Abstract available


  280. SINGH S, Ahmed D, Dolatshad H, Tatwavedi D, et al
    SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.
    Leukemia. 2020 Feb 19. pii: 10.1038/s41375-020-0753.
    PubMed    


  281. HERLING CD, Cymbalista F, Gross-Ophoff-Muller C, Bahlo J, et al
    Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
    Leukemia. 2020 Feb 18. pii: 10.1038/s41375-020-0747.
    PubMed     Abstract available


  282. GODWIN CD, Laszlo GS, Wood BL, Correnti CE, et al
    The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.
    Leukemia. 2020 Feb 18. pii: 10.1038/s41375-020-0755.
    PubMed    


  283. WANDLER AM, Huang BJ, Craig JW, Hayes K, et al
    Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.
    Leukemia. 2020 Feb 17. pii: 10.1038/s41375-020-0748.
    PubMed     Abstract available


  284. AL HINAI ASA, Grob T, Kavelaars FG, Rijken M, et al
    Archived bone marrow smears are an excellent source for NGS-based mutation detection in acute myeloid leukemia.
    Leukemia. 2020 Feb 14. pii: 10.1038/s41375-020-0744.
    PubMed    


  285. OBERLEY MJ, Raikar SS, Wertheim GB, Malvar J, et al
    Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study.
    Leukemia. 2020 Feb 14. pii: 10.1038/s41375-020-0741.
    PubMed     Abstract available


  286. SINNAKANNU JR, Lee KL, Cheng S, Li J, et al
    SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
    Leukemia. 2020 Feb 12. pii: 10.1038/s41375-020-0732.
    PubMed     Abstract available


  287. ROY DC, Walker I, Maertens J, Lewalle P, et al
    ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.
    Leukemia. 2020 Feb 11. pii: 10.1038/s41375-020-0733.
    PubMed     Abstract available


  288. HSIEHCHEN D, Goralski M, Kim J, Xie Y, et al
    Biomarkers for RBM39 degradation in acute myeloid leukemia.
    Leukemia. 2020 Feb 10. pii: 10.1038/s41375-020-0729.
    PubMed    


  289. NADEU F, Royo R, Maura F, Dawson KJ, et al
    Minimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosis.
    Leukemia. 2020 Feb 4. pii: 10.1038/s41375-020-0730.
    PubMed    


  290. RADIVOYEVITCH T, Weaver D, Hobbs B, Maciejewski JP, et al
    Do persons with chronic myeloid leukaemia have normal or near normal survival?
    Leukemia. 2020;34:333-335.
    PubMed    


  291. LANCE A, Druhan LJ, Vestal CG, Steuerwald NM, et al
    Altered expression of CSF3R splice variants impacts signal response and is associated with SRSF2 mutations.
    Leukemia. 2020;34:369-379.
    PubMed     Abstract available


  292. CHATURVEDI A, Goparaju R, Gupta C, Weder J, et al
    In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
    Leukemia. 2020;34:416-426.
    PubMed     Abstract available


  293. CHAO AK, Meyer JA, Lee AG, Hecht A, et al
    Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
    Leukemia. 2020;34:662-666.
    PubMed    


  294. INNES AJ, Woolley P, Szydlo RM, Lozano S, et al
    Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality.
    Leukemia. 2020;34:667-670.
    PubMed    


  295. SKANLAND SS, Cremaschi A, Bendiksen H, Hermansen JU, et al
    An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL.
    Leukemia. 2020;34:478-487.
    PubMed     Abstract available


    January 2020
  296. JACOBS S, Ausema A, Zwart E, Weersing E, et al
    Correction: Quantitative distribution of patient-derived leukemia clones in murine xenografts revealed by cellular barcodes.
    Leukemia. 2020 Jan 31. pii: 10.1038/s41375-020-0722.
    PubMed     Abstract available


  297. KINSTRIE R, Horne GA, Morrison H, Irvine D, et al
    Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
    Leukemia. 2020 Jan 31. pii: 10.1038/s41375-020-0721.
    PubMed     Abstract available


  298. HUET S, Bouvard A, Ferrant E, Mosnier I, et al
    Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia.
    Leukemia. 2020 Jan 29. pii: 10.1038/s41375-020-0716.
    PubMed    


  299. PEMOV A, Pathak A, Jones SJ, Dewan R, et al
    In search of genetic factors predisposing to familial hairy cell leukemia (HCL): exome-sequencing of four multiplex HCL pedigrees.
    Leukemia. 2020 Jan 28. pii: 10.1038/s41375-019-0702.
    PubMed    


  300. YAN B, Chen Q, Xu J, Li W, et al
    Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.
    Leukemia. 2020 Jan 27. pii: 10.1038/s41375-020-0710.
    PubMed     Abstract available


  301. GAZEAU N, Derrieux C, Nibourel O, Berthon C, et al
    Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.
    Leukemia. 2020 Jan 27. pii: 10.1038/s41375-020-0715.
    PubMed    


  302. DANYLESKO I, Jacoby E, Yerushalmi R, Shem-Tov N, et al
    Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells.
    Leukemia. 2020 Jan 24. pii: 10.1038/s41375-020-0719.
    PubMed    


  303. THAN H, Pomicter AD, Yan D, Beaver LP, et al
    Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.
    Leukemia. 2020 Jan 24. pii: 10.1038/s41375-020-0708.
    PubMed    


  304. PFEIFER H, Cazzaniga G, van der Velden VHJ, Cayuela JM, et al
    Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Leukemia. 2020 Jan 14. pii: 10.1038/s41375-020-0707.
    PubMed     Abstract available


  305. ANTAR AI, Otrock ZK, Jabbour E, Mohty M, et al
    FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Leukemia. 2020 Jan 9. pii: 10.1038/s41375-019-0694.
    PubMed     Abstract available


  306. VERMA D, Zanetti C, Godavarthy PS, Kumar R, et al
    Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia.
    Leukemia. 2020 Jan 9. pii: 10.1038/s41375-019-0674.
    PubMed     Abstract available


  307. ESTEY E, Karp JE, Emadi A, Othus M, et al
    Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Leukemia. 2020 Jan 8. pii: 10.1038/s41375-019-0704.
    PubMed     Abstract available


  308. HE H, Kondo Y, Ishiyama K, Alatrash G, et al
    Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.
    Leukemia. 2020 Jan 6. pii: 10.1038/s41375-019-0698.
    PubMed     Abstract available


  309. OPATZ S, Bamopoulos SA, Metzeler KH, Herold T, et al
    The clinical mutatome of core binding factor leukemia.
    Leukemia. 2020 Jan 2. pii: 10.1038/s41375-019-0697.
    PubMed     Abstract available


  310. KINSTRIE R, Horne GA, Morrison H, Irvine D, et al
    CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
    Leukemia. 2020 Jan 2. pii: 10.1038/s41375-019-0684.
    PubMed     Abstract available


  311. RASHIDI A, Kaiser T, Graiziger C, Holtan SG, et al
    Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy.
    Leukemia. 2020;34:312-316.
    PubMed    


  312. KANDA J, Hayashi H, Ruggeri A, Kimura F, et al
    Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.
    Leukemia. 2020;34:128-137.
    PubMed     Abstract available


  313. CUTLER JA, Udainiya S, Madugundu AK, Renuse S, et al
    Integrative phosphoproteome and interactome analysis of the role of Ubash3b in BCR-ABL signaling.
    Leukemia. 2020;34:301-305.
    PubMed    


  314. GILLEECE MH, Labopin M, Savani BN, Yakoub-Agha I, et al
    Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
    Leukemia. 2020;34:87-99.
    PubMed     Abstract available


  315. BISAILLON R, Moison C, Thiollier C, Krosl J, et al
    Genetic characterization of ABT-199 sensitivity in human AML.
    Leukemia. 2020;34:63-74.
    PubMed     Abstract available


  316. YOSIFOV DY, Idler I, Bhattacharya N, Reichenzeller M, et al
    Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.
    Leukemia. 2020;34:115-127.
    PubMed     Abstract available


    December 2019
  317. KIM E, Ten Hacken E, Sivina M, Clarke A, et al
    The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
    Leukemia. 2019 Dec 20. pii: 10.1038/s41375-019-0682.
    PubMed     Abstract available


  318. JACOBS S, Ausema A, Zwart E, Weersing E, et al
    Quantitative distribution of patient-derived leukemia clones in murine xenografts revealed by cellular barcodes.
    Leukemia. 2019 Dec 18. pii: 10.1038/s41375-019-0695.
    PubMed    


  319. SOMERS K, Evans K, Cheung L, Karsa M, et al
    Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.
    Leukemia. 2019 Dec 17. pii: 10.1038/s41375-019-0683.
    PubMed     Abstract available


  320. STONER RC, Press RD, Maxson JE, Tyner JW, et al
    Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.
    Leukemia. 2019 Dec 16. pii: 10.1038/s41375-019-0688.
    PubMed    


  321. COLTRO G, Mangaonkar AA, Lasho TL, Finke CM, et al
    Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Leukemia. 2019 Dec 13. pii: 10.1038/s41375-019-0690.
    PubMed     Abstract available


  322. ARRUGA F, Bracciama V, Vitale N, Vaisitti T, et al
    Correction: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
    Leukemia. 2019 Dec 13. pii: 10.1038/s41375-019-0680.
    PubMed     Abstract available


  323. ERNST T, Rinke J, Hagen J, Dmytrenko I, et al
    Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disaster.
    Leukemia. 2019 Dec 13. pii: 10.1038/s41375-019-0679.
    PubMed    


  324. YU S, Huang F, Wang Y, Xu Y, et al
    Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study.
    Leukemia. 2019 Dec 12. pii: 10.1038/s41375-019-0686.
    PubMed     Abstract available


  325. WANG AJ, Han Y, Jia N, Chen P, et al
    NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia.
    Leukemia. 2019 Dec 12. pii: 10.1038/s41375-019-0681.
    PubMed     Abstract available


  326. MODVIG S, Madsen HO, Siitonen SM, Rosthoj S, et al
    Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Dec 10. pii: 10.1038/s41375-019-0672.
    PubMed     Abstract available


  327. ATTARBASCHI A, Mann G, Zimmermann M, Bader P, et al
    Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
    Leukemia. 2019 Dec 5. pii: 10.1038/s41375-019-0670.
    PubMed    


  328. DESAI R, Taghavi S, Chase JC, Chopra M, et al
    Unexpected variation in leukemia stem cell frequency and genetic heterogeneity in two murine leukemia models initiated by AML1/ETO9a and CALM/AF10.
    Leukemia. 2019 Dec 4. pii: 10.1038/s41375-019-0657.
    PubMed    


  329. MORSINK LM, Bezerra ED, Othus M, Wood BL, et al
    Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease.
    Leukemia. 2019 Dec 3. pii: 10.1038/s41375-019-0671.
    PubMed    


    November 2019
  330. ELCHEVA IA, Wood T, Chiarolanzio K, Chim B, et al
    RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1.
    Leukemia. 2019 Nov 25. pii: 10.1038/s41375-019-0656.
    PubMed     Abstract available


  331. PAGANI IS, Dang P, Saunders VA, Grose R, et al
    Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
    Leukemia. 2019 Nov 25. pii: 10.1038/s41375-019-0647.
    PubMed     Abstract available


  332. BOUVIER A, Riou J, Thepot S, Sutra Del Galy A, et al
    Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.
    Leukemia. 2019 Nov 25. pii: 10.1038/s41375-019-0624.
    PubMed     Abstract available


  333. SAUER MG, Lang PJ, Albert MH, Bader P, et al
    Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.
    Leukemia. 2019 Nov 25. pii: 10.1038/s41375-019-0648.
    PubMed     Abstract available


  334. QUINTARELLI C, Sivori S, Caruso S, Carlomagno S, et al
    Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2019 Nov 19. pii: 10.1038/s41375-019-0613.
    PubMed     Abstract available


  335. BARILA G, Teramo A, Calabretto G, Vicenzetto C, et al
    Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients.
    Leukemia. 2019 Nov 18. pii: 10.1038/s41375-019-0644.
    PubMed     Abstract available


  336. LIEBERS N, Roider T, Bohn JP, Haberbosch I, et al
    BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials.
    Leukemia. 2019 Nov 18. pii: 10.1038/s41375-019-0646.
    PubMed    


  337. KIMURA S, Seki M, Kawai T, Goto H, et al
    DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes.
    Leukemia. 2019 Nov 15. pii: 10.1038/s41375-019-0626.
    PubMed    


  338. FURSTENAU M, Hopfinger G, Robrecht S, Fink AM, et al
    Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
    Leukemia. 2019 Nov 14. pii: 10.1038/s41375-019-0630.
    PubMed    


  339. HARTMANN L, Nadarajah N, Meggendorfer M, Hollein A, et al
    Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.
    Leukemia. 2019 Nov 12. pii: 10.1038/s41375-019-0633.
    PubMed     Abstract available


  340. BUENO-COSTA A, Pineyro D, Soler M, Javierre BM, et al
    B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation.
    Leukemia. 2019 Nov 12. pii: 10.1038/s41375-019-0643.
    PubMed    


  341. MOHTY M, Gautier J, Malard F, Aljurf M, et al
    CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
    Leukemia. 2019 Nov 5. pii: 10.1038/s41375-019-0615.
    PubMed     Abstract available


    October 2019
  342. TATSUMI G, Kawahara M, Imai T, Nishishita-Asai A, et al
    Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15(R138C) knock-in mice.
    Leukemia. 2019 Oct 24. pii: 10.1038/s41375-019-0583.
    PubMed     Abstract available


  343. ELSAYED AH, Rafiee R, Cao X, Raimondi S, et al
    A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
    Leukemia. 2019 Oct 23. pii: 10.1038/s41375-019-0604.
    PubMed     Abstract available


  344. KOTROVA M, Volland A, Kehden B, Trautmann H, et al
    Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia.
    Leukemia. 2019 Oct 22. pii: 10.1038/s41375-019-0599.
    PubMed    


  345. YOUNG KH
    Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?
    Leukemia. 2019 Oct 22. pii: 10.1038/s41375-019-0608.
    PubMed    


  346. VORBACH S, Grunder A, Zhou F, Koellerer C, et al
    Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice.
    Leukemia. 2019 Oct 21. pii: 10.1038/s41375-019-0577.
    PubMed     Abstract available


  347. JONAS BA, Pollyea DA
    How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
    Leukemia. 2019 Oct 18. pii: 10.1038/s41375-019-0612.
    PubMed     Abstract available


  348. JIN X, Cao Y, Wang L, Sun R, et al
    HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
    Leukemia. 2019 Oct 18. pii: 10.1038/s41375-019-0610.
    PubMed    


  349. SAIDA S, Zhen T, Kim E, Yu K, et al
    Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
    Leukemia. 2019 Oct 17. pii: 10.1038/s41375-019-0605.
    PubMed     Abstract available


  350. DURRANI J, Awada H, Kishtagari A, Visconte V, et al
    Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome.
    Leukemia. 2019 Oct 17. pii: 10.1038/s41375-019-0601.
    PubMed    


  351. LEUNG KT, Zhang C, Chan KYY, Li K, et al
    CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity.
    Leukemia. 2019 Oct 17. pii: 10.1038/s41375-019-0593.
    PubMed     Abstract available


  352. ALANAZI B, Munje CR, Rastogi N, Williamson AJK, et al
    Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0596.
    PubMed     Abstract available


  353. FURSTENAU M, Bahlo J, Fink AM, Lange E, et al
    Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0597.
    PubMed    


  354. QUIST-PAULSEN P, Toft N, Heyman M, Abrahamsson J, et al
    T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0598.
    PubMed     Abstract available


  355. CICCONI L, Platzbecker U, Avvisati G, Paoloni F, et al
    Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0589.
    PubMed    


  356. WU Z, Sun H, Liu W, Zhu H, et al
    Circ-RPL15: a plasma circular RNA as novel oncogenic driver to promote progression of chronic lymphocytic leukemia.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0594.
    PubMed    


  357. BACCARANI M, Iacobucci I, Chiaretti S, Foa' R, et al
    In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent.
    Leukemia. 2019 Oct 8. pii: 10.1038/s41375-019-0591.
    PubMed    


  358. TUMINO N, Besi F, Di Pace AL, Mariotti FR, et al
    PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation.
    Leukemia. 2019 Oct 4. pii: 10.1038/s41375-019-0585.
    PubMed    


  359. HALPERN AB, Howard NP, Othus M, Hendrie PC, et al
    Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.
    Leukemia. 2019 Oct 4. pii: 10.1038/s41375-019-0586.
    PubMed    


  360. SAUER MG, Lang PJ, Albert MH, Bader P, et al
    Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.
    Leukemia. 2019 Oct 2. pii: 10.1038/s41375-019-0584.
    PubMed     Abstract available


  361. MEYER T, Jahn N, Lindner S, Rohner L, et al
    Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).
    Leukemia. 2019 Oct 1. pii: 10.1038/s41375-019-0578.
    PubMed     Abstract available


  362. KARJALAINEN R, Liu M, Kumar A, He L, et al
    Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
    Leukemia. 2019;33:2548-2553.
    PubMed    


  363. BLATTE TJ, Schmalbrock LK, Skambraks S, Lux S, et al
    getITD for FLT3-ITD-based MRD monitoring in AML.
    Leukemia. 2019;33:2535-2539.
    PubMed    


  364. CHRISTIAN S, Merz C, Evans L, Gradl S, et al
    The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
    Leukemia. 2019;33:2403-2415.
    PubMed     Abstract available


  365. MALLANEY C, Ostrander EL, Celik H, Kramer AC, et al
    Kdm6b regulates context-dependent hematopoietic stem cell self-renewal and leukemogenesis.
    Leukemia. 2019;33:2506-2521.
    PubMed     Abstract available


    September 2019
  366. THASTRUP M, Marquart HV, Levinsen M, Grell K, et al
    Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.
    Leukemia. 2019 Sep 18. pii: 10.1038/s41375-019-0570.
    PubMed     Abstract available


  367. AZADNIV M, Myers JR, McMurray HR, Guo N, et al
    Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support.
    Leukemia. 2019 Sep 6. pii: 10.1038/s41375-019-0568.
    PubMed     Abstract available


  368. ZHANG Z, Li L, Wu C, Yin G, et al
    Inhibition of Slug effectively targets leukemia stem cells via the Slc13a3/ROS signaling pathway.
    Leukemia. 2019 Sep 6. pii: 10.1038/s41375-019-0566.
    PubMed     Abstract available


  369. EFFICACE F, Stagno F, Iurlo A, Breccia M, et al
    Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
    Leukemia. 2019 Sep 2. pii: 10.1038/s41375-019-0563.
    PubMed     Abstract available


  370. BRUGGEMANN M, Kotrova M, Knecht H, Bartram J, et al
    Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
    Leukemia. 2019;33:2241-2253.
    PubMed     Abstract available


  371. MEYER C, Lopes BA, Caye-Eude A, Cave H, et al
    Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions.
    Leukemia. 2019;33:2306-2340.
    PubMed    


    August 2019
  372. ARRUGA F, Bracciama V, Vitale N, Vaisitti T, et al
    Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
    Leukemia. 2019 Aug 29. pii: 10.1038/s41375-019-0571.
    PubMed     Abstract available


  373. ENYA CHEN YC, Burgess M, Mapp S, Mollee P, et al
    PI3K-p110delta contributes to antibody responses by macrophages in chronic lymphocytic leukemia.
    Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0556.
    PubMed     Abstract available


  374. AGRAWAL M, Schwarz P, Giaimo BD, Bedzhov I, et al
    Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
    Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0551.
    PubMed    


  375. SMITH LD, Minton AR, Blunt MD, Karydis LI, et al
    BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia.
    Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0557.
    PubMed    


  376. BHATNAGAR B, Eisfeld AK, Kohlschmidt J, Mrozek K, et al
    Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.
    Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0560.
    PubMed     Abstract available


  377. BACCARANI M, Rosti G, Soverini S
    Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.
    Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0562.
    PubMed     Abstract available


  378. BOSCH F, Cantin G, Cortelezzi A, Knauf W, et al
    Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.
    Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0554.
    PubMed     Abstract available


  379. WEISBERG E, Meng C, Case A, Sattler M, et al
    Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
    Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0552.
    PubMed    


  380. CAZZOLA A, Schlegel C, Jansen I, Bochtler T, et al
    TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.
    Leukemia. 2019 Aug 23. pii: 10.1038/s41375-019-0550.
    PubMed     Abstract available


  381. HIXON JA, Andrews C, Kashi L, Kohnhorst CL, et al
    New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.
    Leukemia. 2019 Aug 22. pii: 10.1038/s41375-019-0531.
    PubMed     Abstract available


  382. KIM JC, Zuzarte PC, Murphy T, Chan-Seng-Yue M, et al
    Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencing.
    Leukemia. 2019 Aug 21. pii: 10.1038/s41375-019-0546.
    PubMed    


  383. OFRAN Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, et al
    Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.
    Leukemia. 2019 Aug 21. pii: 10.1038/s41375-019-0548.
    PubMed    


  384. AWADA H, Rahman S, Durrani J, Asad MF, et al
    Leukemia evolving from paroxysmal nocturnal hemoglobinuria.
    Leukemia. 2019 Aug 20. pii: 10.1038/s41375-019-0555.
    PubMed    


  385. KREUZER KA, Furman RR, Stilgenbauer S, Dubowy RL, et al
    The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
    Leukemia. 2019 Aug 19. pii: 10.1038/s41375-019-0533.
    PubMed    


  386. SHEM-TOV N, Peczynski C, Labopin M, Itala-Remes M, et al
    Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT.
    Leukemia. 2019 Aug 19. pii: 10.1038/s41375-019-0544.
    PubMed     Abstract available


  387. KUEPPER MK, Butow M, Herrmann O, Ziemons J, et al
    Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.
    Leukemia. 2019;33:1964-1977.
    PubMed     Abstract available


  388. SINCLAIR PB, Ryan S, Bashton M, Hollern S, et al
    SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain.
    Leukemia. 2019;33:1881-1894.
    PubMed     Abstract available


  389. ESCUDERO L, Cleal K, Ashelford K, Fegan C, et al
    Telomere fusions associate with coding sequence and copy number alterations in CLL.
    Leukemia. 2019;33:2093-2097.
    PubMed    


  390. SCHLENK RF, Weber D, Herr W, Wulf G, et al
    Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.
    Leukemia. 2019;33:1923-1933.
    PubMed     Abstract available


  391. YASSIN M, Aqaqe N, Yassin AA, van Galen P, et al
    A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity.
    Leukemia. 2019;33:2061-2077.
    PubMed     Abstract available


  392. NORRIS K, Hillmen P, Rawstron A, Hills R, et al
    Telomere length predicts for outcome to FCR chemotherapy in CLL.
    Leukemia. 2019;33:1953-1963.
    PubMed     Abstract available


  393. SHIELDS BJ, Slape CI, Vo N, Jackson JT, et al
    The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.
    Leukemia. 2019;33:1868-1880.
    PubMed     Abstract available


  394. RACK KA, van den Berg E, Haferlach C, Beverloo HB, et al
    European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.
    Leukemia. 2019;33:1851-1867.
    PubMed     Abstract available


    July 2019
  395. WANG S, Ge M, Cui J, Qiao Z, et al
    Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia.
    Leukemia. 2019 Jul 24. pii: 10.1038/s41375-019-0526.
    PubMed    


  396. ADVANI PG, Schonfeld SJ, Curtis RE, Dores GM, et al
    Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study.
    Leukemia. 2019 Jul 24. pii: 10.1038/s41375-019-0520.
    PubMed    


  397. WANG H, Zhao D, Nguyen LX, Wu H, et al
    Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
    Leukemia. 2019 Jul 23. pii: 10.1038/s41375-019-0522.
    PubMed     Abstract available


  398. CAO J, Cheng H, Shi M, Wang G, et al
    Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Jul 15. pii: 10.1038/s41375-019-0516.
    PubMed    


  399. DE SMITH AJ, Walsh KM, Morimoto LM, Francis SS, et al
    Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome.
    Leukemia. 2019 Jul 11. pii: 10.1038/s41375-019-0514.
    PubMed    


  400. ZHANG MM, Liu N, Zhang YL, Rong B, et al
    Destabilization of AETFC through C/EBPalpha-mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation.
    Leukemia. 2019;33:1822-1827.
    PubMed    


  401. SPORTOLETTI P, Celani L, Varasano E, Rossi R, et al
    GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations.
    Leukemia. 2019;33:1827-1832.
    PubMed    


  402. LOBERG MA, Bell RK, Goodwin LO, Eudy E, et al
    Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
    Leukemia. 2019;33:1635-1649.
    PubMed     Abstract available


  403. HOHTARI H, Bruck O, Blom S, Turkki R, et al
    Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL.
    Leukemia. 2019;33:1570-1582.
    PubMed     Abstract available


    June 2019
  404. BRANFORD S, Kim DDH, Apperley JF, Eide CA, et al
    Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
    Leukemia. 2019 Jun 17. pii: 10.1038/s41375-019-0512.
    PubMed     Abstract available


  405. STIEF SM, Hanneforth AL, Weser S, Mattes R, et al
    Loss of KDM6A confers drug resistance in acute myeloid leukemia.
    Leukemia. 2019 Jun 14. pii: 10.1038/s41375-019-0497.
    PubMed     Abstract available


  406. GIMENEZ N, Schulz R, Higashi M, Aymerich M, et al
    Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
    Leukemia. 2019 Jun 13. pii: 10.1038/s41375-019-0507.
    PubMed     Abstract available


  407. ANGENENDT L, Bormann E, Pabst C, Alla V, et al
    The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
    Leukemia. 2019 Jun 10. pii: 10.1038/s41375-019-0505.
    PubMed     Abstract available


  408. BARTH J, Abou-El-Ardat K, Dalic D, Kurrle N, et al
    LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Leukemia. 2019;33:1411-1426.
    PubMed     Abstract available


  409. LYNCH JR, Salik B, Connerty P, Vick B, et al
    JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
    Leukemia. 2019;33:1400-1410.
    PubMed     Abstract available


  410. DUBOIS A, Furstoss N, Calleja A, Zerhouni M, et al
    LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.
    Leukemia. 2019;33:1501-1513.
    PubMed     Abstract available


  411. SAENZ DT, Fiskus W, Manshouri T, Mill CP, et al
    Targeting nuclear beta-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
    Leukemia. 2019;33:1373-1386.
    PubMed     Abstract available


    May 2019
  412. TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
    Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.
    Leukemia. 2019 May 30. pii: 10.1038/s41375-019-0494.
    PubMed     Abstract available


  413. ARMENTEROS-MONTERROSO E, Zhao L, Gasparoli L, Brooks T, et al
    The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
    Leukemia. 2019 May 28. pii: 10.1038/s41375-019-0495.
    PubMed     Abstract available


  414. NII T, Prabhu VV, Ruvolo V, Madhukar N, et al
    Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
    Leukemia. 2019 May 24. pii: 10.1038/s41375-019-0491.
    PubMed     Abstract available


  415. HOUSHMAND M, Simonetti G, Circosta P, Gaidano V, et al
    Chronic myeloid leukemia stem cells.
    Leukemia. 2019 May 24. pii: 10.1038/s41375-019-0490.
    PubMed     Abstract available


  416. PAN J, Niu Q, Deng B, Liu S, et al
    CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
    Leukemia. 2019 May 20. pii: 10.1038/s41375-019-0488.
    PubMed     Abstract available


  417. STILGENBAUER S, Aurran Schleinitz T, Eichhorst B, Lang F, et al
    Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
    Leukemia. 2019 May 14. pii: 10.1038/s41375-019-0475.
    PubMed    


  418. USTUN C, Le-Rademacher J, Wang HL, Othus M, et al
    Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
    Leukemia. 2019 May 9. pii: 10.1038/s41375-019-0477.
    PubMed     Abstract available


  419. BATALLER A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G, et al
    The role of TGFbeta in hematopoiesis and myeloid disorders.
    Leukemia. 2019;33:1076-1089.
    PubMed     Abstract available


  420. POTTER N, Miraki-Moud F, Ermini L, Titley I, et al
    Single cell analysis of clonal architecture in acute myeloid leukaemia.
    Leukemia. 2019;33:1113-1123.
    PubMed     Abstract available


  421. WANG TT, Yang J, Zhang Y, Zhang M, et al
    IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective gamma-chain cytokines, decreases leukemic T-cell viability.
    Leukemia. 2019;33:1243-1255.
    PubMed     Abstract available


  422. PAGANO MA, Tibaldi E, Molino P, Frezzato F, et al
    Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.
    Leukemia. 2019;33:1148-1160.
    PubMed     Abstract available


    April 2019
  423. POLLYEA DA, Tallman MS, de Botton S, Kantarjian HM, et al
    Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0472.
    PubMed     Abstract available


  424. DONG Y, Zhao X, Feng X, Zhou Y, et al
    SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0456.
    PubMed     Abstract available


  425. KLEIN K, Witalisz-Siepracka A, Maurer B, Prinz D, et al
    STAT5B(N642H) drives transformation of NKT cells: a novel mouse model for CD56(+) T-LGL leukemia.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0471.
    PubMed    


  426. LIN M, Nebral K, Gertzen CGW, Ganmore I, et al
    JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0459.
    PubMed    


  427. HYRENIUS-WITTSTEN A, Pilheden M, Falques-Costa A, Eriksson M, et al
    FLT3(N676K) drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0465.
    PubMed    


  428. EISENWORT G, Sadovnik I, Schwaab J, Jawhar M, et al
    Identification of a leukemia-initiating stem cell in human mast cell leukemia.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0460.
    PubMed     Abstract available


  429. TIAN XP, Huang WJ, Huang HQ, Liu YH, et al
    Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0466.
    PubMed     Abstract available


  430. CHEN YL, Tang C, Zhang MY, Huang WL, et al
    Blocking ATM-dependent NF-kappaB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia.
    Leukemia. 2019 Apr 2. pii: 10.1038/s41375-019-0458.
    PubMed     Abstract available


  431. FALINI B, Spinelli O, Meggendorfer M, Martelli MP, et al
    IDH1-R132 changes vary according to NPM1 and other mutations status in AML.
    Leukemia. 2019;33:1043-1047.
    PubMed    


  432. POTTER N, Jones L, Blair H, Strehl S, et al
    Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.
    Leukemia. 2019;33:893-904.
    PubMed     Abstract available


  433. ZABORSKY N, Gassner FJ, Hopner JP, Schubert M, et al
    Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
    Leukemia. 2019;33:957-968.
    PubMed     Abstract available


  434. DORON B, Abdelhamed S, Butler JT, Hashmi SK, et al
    Transmissible ER stress reconfigures the AML bone marrow compartment.
    Leukemia. 2019;33:918-930.
    PubMed     Abstract available


  435. BAQUERO P, Dawson A, Mukhopadhyay A, Kuntz EM, et al
    Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
    Leukemia. 2019;33:981-994.
    PubMed     Abstract available


    March 2019
  436. EL-JAWAHRI A, Abel GA, Traeger L, Waldman L, et al
    Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
    Leukemia. 2019 Mar 28. pii: 10.1038/s41375-019-0449.
    PubMed     Abstract available


  437. JEBARAJ BMC, Tausch E, Landau DA, Bahlo J, et al
    Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.
    Leukemia. 2019 Mar 25. pii: 10.1038/s41375-019-0446.
    PubMed     Abstract available


  438. VISHWAKARMA BA, Gudmundsson KO, Oakley K, Han Y, et al
    Insertional mutagenesis identifies cooperation between Setbp1 and Mllt3 in inducing myeloid leukemia development.
    Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0445.
    PubMed    


  439. LUCAS N, Duchmann M, Rameau P, Noel F, et al
    Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.
    Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0447.
    PubMed     Abstract available


  440. RADPOUR R, Riether C, Simillion C, Hopner S, et al
    CD8(+) T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia.
    Leukemia. 2019 Mar 15. pii: 10.1038/s41375-019-0441.
    PubMed     Abstract available


  441. JANSSEN L, Frambach SJCM, Allard NAE, Hopman MTE, et al
    Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0443.
    PubMed    


  442. VENDRAMINI E, Bomben R, Pozzo F, Benedetti D, et al
    KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0444.
    PubMed    


  443. PFEIFER H, Cazzaniga G, van der Velden VHJ, Cayuela JM, et al
    Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0413.
    PubMed     Abstract available


  444. BILL M, Papaioannou D, Karunasiri M, Kohlschmidt J, et al
    Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.
    Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0429.
    PubMed     Abstract available


  445. AKKAPEDDI P, Fragoso R, Hixon JA, Ramalho AS, et al
    A fully human anti-IL-7Ralpha antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 8. pii: 10.1038/s41375-019-0434.
    PubMed     Abstract available


  446. HE X, Xiao X, Li Q, Jiang Y, et al
    Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0437.
    PubMed    


  447. CANAANI J, Labopin M, Itala-Remes M, Blaise D, et al
    Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0439.
    PubMed     Abstract available


  448. BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
    Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0426.
    PubMed     Abstract available


  449. BASTIAN L, Schroeder MP, Eckert C, Schlee C, et al
    PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 6. pii: 10.1038/s41375-019-0430.
    PubMed     Abstract available


  450. KOTANI S, Yoda A, Kon A, Kataoka K, et al
    Molecular pathogenesis of disease progression in MLL-rearranged AML.
    Leukemia. 2019;33:612-624.
    PubMed     Abstract available


  451. KONG G, You X, Wen Z, Chang YI, et al
    Downregulating Notch counteracts Kras(G12D)-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm.
    Leukemia. 2019;33:671-685.
    PubMed     Abstract available


  452. BENAJIBA L, Alexe G, Su A, Raffoux E, et al
    Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.
    Leukemia. 2019;33:800-804.
    PubMed    


  453. HUMBERT O, Laszlo GS, Sichel S, Ironside C, et al
    Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.
    Leukemia. 2019;33:762-808.
    PubMed    


    February 2019
  454. STEINHERZ PG, Seibel NL, Sather H, Ji L, et al
    Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.
    Leukemia. 2019 Feb 28. pii: 10.1038/s41375-019-0422.
    PubMed     Abstract available


  455. BUENO C, Velasco-Hernandez T, Gutierrez-Aguera F, Zanetti SR, et al
    CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.
    Leukemia. 2019 Feb 18. pii: 10.1038/s41375-019-0418.
    PubMed    


  456. MCNEER NA, Philip J, Geiger H, Ries RE, et al
    Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.
    Leukemia. 2019 Feb 13. pii: 10.1038/s41375-019-0402.
    PubMed     Abstract available


  457. MROZEK K, Eisfeld AK, Kohlschmidt J, Carroll AJ, et al
    Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.
    Leukemia. 2019 Feb 8. pii: 10.1038/s41375-019-0390.
    PubMed     Abstract available


  458. BENARD B, Gentles AJ, Kohnke T, Majeti R, et al
    Data mining for mutation-specific targets in acute myeloid leukemia.
    Leukemia. 2019 Feb 6. pii: 10.1038/s41375-019-0387.
    PubMed     Abstract available


  459. GUENOT C, Lacombe F, Allou K, Dumezy F, et al
    Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.
    Leukemia. 2019 Feb 5. pii: 10.1038/s41375-019-0393.
    PubMed    


  460. DAVER N, Schlenk RF, Russell NH, Levis MJ, et al
    Targeting FLT3 mutations in AML: review of current knowledge and evidence.
    Leukemia. 2019;33:299-312.
    PubMed     Abstract available


  461. HOURIGAN CS, Gale RP, Walter RB
    Refining AML outcome prediction.
    Leukemia. 2019;33:283-284.
    PubMed    


  462. HERNANDEZ-SANCHEZ M, Kotaskova J, Rodriguez AE, Radova L, et al
    CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase.
    Leukemia. 2019;33:518-558.
    PubMed    


  463. BORGA C, Park G, Foster C, Burroughs-Garcia J, et al
    Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis.
    Leukemia. 2019;33:333-347.
    PubMed     Abstract available


  464. CERNA K, Oppelt J, Chochola V, Musilova K, et al
    MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
    Leukemia. 2019;33:403-414.
    PubMed     Abstract available


  465. ENGEL N, Rovo A, Badoglio M, Labopin M, et al
    European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation.
    Leukemia. 2019;33:508-517.
    PubMed     Abstract available


  466. KAMPEN KR, Sulima SO, Verbelen B, Girardi T, et al
    The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
    Leukemia. 2019;33:319-332.
    PubMed     Abstract available


    January 2019
  467. MASCHMEYER G, De Greef J, Mellinghoff SC, Nosari A, et al
    Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).
    Leukemia. 2019 Jan 30. pii: 10.1038/s41375-019-0388.
    PubMed     Abstract available


  468. CHEN R, Zhu M, Chaudhari RR, Robles O, et al
    Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
    Leukemia. 2019 Jan 30. pii: 10.1038/s41375-018-0364.
    PubMed     Abstract available


  469. SHI Y, Wang G, Muhowski EM, McCaw L, et al
    Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
    Leukemia. 2019 Jan 29. pii: 10.1038/s41375-019-0381.
    PubMed     Abstract available


  470. SCHMIDT L, Heyes E, Scheiblecker L, Eder T, et al
    CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-019-0382.
    PubMed     Abstract available


  471. KROMBHOLZ CF, Gallego-Villar L, Sahoo SS, Panda PK, et al
    Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0343.
    PubMed    


  472. MOYSIADIS T, Baliakas P, Rossi D, Catherwood M, et al
    Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen b-receptors.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0322.
    PubMed    


  473. KOLLMANN S, Grundschober E, Maurer B, Warsch W, et al
    Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0369.
    PubMed     Abstract available


  474. HOFFMANN H, Thiede C, Glauche I, Kramer M, et al
    The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0371.
    PubMed    


  475. NABINGER SC, Chen S, Gao R, Yao C, et al
    Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-019-0377.
    PubMed    


  476. BACCARANI M, Castagnetti F, Gugliotta G, Rosti G, et al
    The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0341.
    PubMed     Abstract available


  477. ESTEY E, Othus M, Gale RP
    New study-designs to address the clinical complexity of acute myeloid leukemia.
    Leukemia. 2019 Jan 22. pii: 10.1038/s41375-018-0363.
    PubMed    


  478. FIORCARI S, Benatti S, Zucchetto A, Zucchini P, et al
    Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS.
    Leukemia. 2019 Jan 18. pii: 10.1038/s41375-018-0296.
    PubMed    


  479. ALFONSO V, Iaccarino L, Ottone T, Cicconi L, et al
    Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
    Leukemia. 2019 Jan 16. pii: 10.1038/s41375-018-0298.
    PubMed    


  480. LOPEZ-MILLAN B, Sanchez-Martinez D, Roca-Ho H, Gutierrez-Aguera F, et al
    NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0353.
    PubMed     Abstract available


  481. JAWHAR M, Dohner K, Kreil S, Schwaab J, et al
    KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0346.
    PubMed     Abstract available


  482. REDA G, Cassin R, Gentile M, Mauro FR, et al
    IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0344.
    PubMed    


  483. OZTURK S, Roessner PM, Schulze-Edinghausen L, Yazdanparast H, et al
    Rejection of adoptively transferred Emicro-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0332.
    PubMed    


  484. HOANG VT, Verma D, Godavarthy PS, Llavona P, et al
    The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0358.
    PubMed     Abstract available


  485. GOUNARI M, Ntoufa S, Gerousi M, Vilia MG, et al
    Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
    Leukemia. 2019 Jan 3. pii: 10.1038/s41375-018-0335.
    PubMed    


  486. NIYONGERE S, Lucas N, Zhou JM, Sansil S, et al
    Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.
    Leukemia. 2019;33:205-216.
    PubMed     Abstract available


  487. DWIVEDI P, Muench DE, Wagner M, Azam M, et al
    Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.
    Leukemia. 2019;33:75-87.
    PubMed     Abstract available


  488. HAUBNER S, Perna F, Kohnke T, Schmidt C, et al
    Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
    Leukemia. 2019;33:64-74.
    PubMed     Abstract available


  489. ARAKI M, Yang Y, Imai M, Mizukami Y, et al
    Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
    Leukemia. 2019;33:122-131.
    PubMed     Abstract available


  490. SCHNEIDT V, Ilecka M, Dreger P, van Zyl DG, et al
    Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo.
    Leukemia. 2019;33:88-98.
    PubMed     Abstract available


  491. FRASZCZAK J, Vadnais C, Rashkovan M, Ross J, et al
    Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice.
    Leukemia. 2019;33:110-121.
    PubMed     Abstract available


  492. SHIMONI A, Labopin M, Lorentino F, Van Lint MT, et al
    Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
    Leukemia. 2019;33:230-239.
    PubMed     Abstract available


    December 2018
  493. ZHAO J, Liang JW, Xue HL, Shen SH, et al
    The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
    Leukemia. 2018 Dec 21. pii: 10.1038/s41375-018-0338.
    PubMed     Abstract available


  494. VELAZQUEZ-AVILA M, Balandran JC, Ramirez-Ramirez D, Velazquez-Avila M, et al
    High cortactin expression in B-cell acute lymphoblastic leukemia is associated with increased transendothelial migration and bone marrow relapse.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0333.
    PubMed     Abstract available


  495. SCHETELIG J, de Wreede LC, van Gelder M, Koster L, et al
    Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0302.
    PubMed     Abstract available


  496. EFFICACE F, Breccia M, Avvisati G, Cottone F, et al
    Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0325.
    PubMed     Abstract available


  497. BORGA C, Foster CA, Iyer S, Garcia SP, et al
    Molecularly distinct models of zebrafish Myc-induced B cell leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0328.
    PubMed    


  498. HANNA BS, Roessner PM, Scheffold A, Jebaraj BMC, et al
    PI3Kdelta inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0318.
    PubMed     Abstract available


  499. VON TRESCKOW J, Cramer P, Bahlo J, Robrecht S, et al
    CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0313.
    PubMed     Abstract available


  500. KIVIOJA JL, Thanasopoulou A, Kumar A, Kontro M, et al
    Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0327.
    PubMed     Abstract available


  501. REEDIJK AMJ, Klein K, Coebergh JWW, Kremer LC, et al
    Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0314.
    PubMed     Abstract available


  502. HASAN MK, Rassenti L, Widhopf GF 2nd, Yu J, et al
    Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0306.
    PubMed     Abstract available


  503. CORTES JE, Heidel FH, Hellmann A, Fiedler W, et al
    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0312.
    PubMed     Abstract available


  504. PARK JH, Woo YM, Youm EM, Hamad N, et al
    HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0321.
    PubMed     Abstract available


  505. TEN HACKEN E, Gounari M, Ghia P, Burger JA, et al
    The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0303.
    PubMed     Abstract available


  506. MODVIG S, Madsen HO, Siitonen SM, Rosthoj S, et al
    Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 14. pii: 10.1038/s41375-018-0307.
    PubMed     Abstract available


  507. SCHERR M, Kirchhoff H, Battmer K, Wohlan K, et al
    Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0315.
    PubMed     Abstract available


  508. ANDERSEN MA, Moser CE, Lundgren J, Niemann CU, et al
    Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0316.
    PubMed     Abstract available


  509. ZEIJLEMAKER W, Grob T, Meijer R, Hanekamp D, et al
    CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
    Leukemia. 2018 Dec 12. pii: 10.1038/s41375-018-0326.
    PubMed     Abstract available


  510. HU X, Xu S, Chen Y, Gao Z, et al
    Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis.
    Leukemia. 2018 Dec 5. pii: 10.1038/s41375-018-0301.
    PubMed     Abstract available


    November 2018
  511. BLAGITKO-DORFS N, Schlosser P, Greve G, Pfeifer D, et al
    Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
    Leukemia. 2018 Nov 23. pii: 10.1038/s41375-018-0293.
    PubMed     Abstract available


    October 2018
  512. CAESER R, Collord G, Yao WQ, Chen Z, et al
    Targeting MEK in vemurafenib-resistant hairy cell leukemia.
    Leukemia. 2018 Oct 19. pii: 10.1038/s41375-018-0270.
    PubMed    


  513. KRAFT B, Lombard J, Kirsch M, Wuchter P, et al
    SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia.
    Leukemia. 2018 Oct 15. pii: 10.1038/s41375-018-0287.
    PubMed    


  514. FRASER G, Cramer P, Demirkan F, Silva RS, et al
    Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
    PubMed     Abstract available


  515. OTHUS M, Sekeres MA, Nand S, Garcia-Manero G, et al
    Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0275.
    PubMed     Abstract available


  516. OTHUS M, Estey EH, Garcia-Manero G, Wood BL, et al
    Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0274.
    PubMed    


  517. ROSS DM, Pagani IS, Shanmuganathan N, Kok CH, et al
    Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0264.
    PubMed     Abstract available


  518. MANSO BA, Zhang H, Mikkelson MG, Gwin KA, et al
    Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0280.
    PubMed     Abstract available


  519. YAN B, Chen Q, Shimada K, Tang M, et al
    Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0279.
    PubMed     Abstract available


  520. WALKER CJ, Oakes CC, Genutis LK, Giacopelli B, et al
    Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0281.
    PubMed    


  521. BRAESS J, Amler S, Kreuzer KA, Spiekermann K, et al
    Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0268.
    PubMed     Abstract available


  522. DOHNER H, Dolnik A, Tang L, Seymour JF, et al
    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0257.
    PubMed     Abstract available


  523. VANDEPOELE K, Van der Meulen J, Denys B
    The NF1 hotspot in acute myeloid leukemia: what's in a name?
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0266.
    PubMed    


    September 2018
  524. BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
    Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0265.
    PubMed     Abstract available


  525. HANNA BS, Roessner PM, Yazdanparast H, Colomer D, et al
    Control of chronic lymphocytic leukemia development by clonally-expanded CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues.
    Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0250.
    PubMed     Abstract available


  526. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
    Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0237.
    PubMed     Abstract available


  527. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
    Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0241.
    PubMed     Abstract available


  528. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2018 Sep 14. pii: 10.1038/s41375-018-0236.
    PubMed     Abstract available


  529. KLUPSCH K, Baeriswyl V, Scholz R, Dannenberg J, et al
    COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
    Leukemia. 2018 Sep 11. pii: 10.1038/s41375-018-0249.
    PubMed    


  530. MOUJALLED DM, Pomilio G, Ghiurau C, Ivey A, et al
    Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0261.
    PubMed     Abstract available


  531. AGHEL N, Delgado DH, Lipton JH
    Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
    Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0247.
    PubMed     Abstract available


    August 2018
  532. TAKESHITA A, Asou N, Atsuta Y, Sakura T, et al
    Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.
    Leukemia. 2018 Aug 9. pii: 10.1038/s41375-018-0233.
    PubMed     Abstract available


  533. DUPLOYEZ N, Marceau-Renaut A, Villenet C, Petit A, et al
    The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Leukemia. 2018 Aug 8. pii: 10.1038/s41375-018-0227.
    PubMed     Abstract available


  534. PATNAIK MM, Tefferi A, Garcia-Manero G
    Blast-phase chronic myelomonocytic leukemia: more than just semantics.
    Leukemia. 2018 Aug 7. pii: 10.1038/s41375-018-0228.
    PubMed    


  535. KURTZ SE, Eide CA, Kaempf A, Mori M, et al
    Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.
    Leukemia. 2018 Aug 6. pii: 10.1038/s41375-018-0225.
    PubMed    


    July 2018
  536. LEEKSMA AC, Taylor J, Wu B, Gardner JR, et al
    Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
    Leukemia. 2018 Jul 23. pii: 10.1038/s41375-018-0215.
    PubMed     Abstract available


  537. KREITMAN RJ, Dearden C, Zinzani PL, Delgado J, et al
    Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
    Leukemia. 2018 Jul 20. pii: 10.1038/s41375-018-0210.
    PubMed     Abstract available


  538. ALDOSS I, Capelletti M, Park J, Pistofidis RS, et al
    Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.
    Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0213.
    PubMed     Abstract available


  539. CICCONI L, Fenaux P, Kantarjian H, Tallman M, et al
    Molecular remission as a therapeutic objective in acute promyelocytic leukemia.
    Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0219.
    PubMed     Abstract available


  540. LI Z, He S, Look AT
    The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
    Leukemia. 2018 Jul 15. pii: 10.1038/s41375-018-0201.
    PubMed    


  541. L'ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2018 Jul 9. pii: 10.1038/s41375-018-0177.
    PubMed     Abstract available


  542. STUDD JB, Yang M, Li Z, Vijayakrishnan J, et al
    Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism.
    Leukemia. 2018 Jul 6. pii: 10.1038/s41375-018-0184.
    PubMed     Abstract available


  543. LUNDIN-STROM KB, Biloglav A, Lilljebjorn H, Rissler M, et al
    Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Jul 2. pii: 10.1038/s41375-018-0191.
    PubMed    


    June 2018
  544. VICENTE-DUENAS C, Gonzalez-Herrero I, Sehgal L, Garcia-Ramirez I, et al
    Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia.
    Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0192.
    PubMed    


  545. MARGOLSKEE E
    So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology.
    Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0186.
    PubMed    


  546. BOND J, Labis E, Marceau-Renaut A, Duployez N, et al
    Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.
    Leukemia. 2018 Jun 27. pii: 10.1038/s41375-018-0187.
    PubMed    


  547. HOLMQVIST AS, Chen Y, Wu J, Kung M, et al
    Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.
    Leukemia. 2018 Jun 26. pii: 10.1038/s41375-018-0171.
    PubMed    


  548. CRIADO I, Blanco E, Rodriguez-Caballero A, Alcoceba M, et al
    Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.
    Leukemia. 2018 Jun 21. pii: 10.1038/s41375-018-0164.
    PubMed    


  549. SUTTORP M, Schulze P, Glauche I, Gohring G, et al
    Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0179.
    PubMed     Abstract available


  550. GEBHARD C, Glatz D, Schwarzfischer L, Wimmer J, et al
    Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0165.
    PubMed     Abstract available


  551. ERNST T, Busch M, Rinke J, Ernst J, et al
    Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.
    Leukemia. 2018 Jun 13. pii: 10.1038/s41375-018-0157.
    PubMed    


  552. BODDU P, Gurguis C, Sanford D, Cortes J, et al
    Response kinetics and factors predicting survival in core-binding factor leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0158.
    PubMed    


  553. BOUDREAUX SP, Duren RP, Call SG, Nguyen L, et al
    Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0174.
    PubMed     Abstract available


  554. TASIAN SK, Casas JA, Posocco D, Gandre-Babbe S, et al
    Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0169.
    PubMed     Abstract available


  555. TIMILSHINA N, Breunis H, Tomlinson GA, Brandwein JM, et al
    Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0162.
    PubMed     Abstract available


  556. BARGHOUT SH, Patel PS, Wang X, Xu GW, et al
    Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0167.
    PubMed     Abstract available


  557. EISFELD AK, Kohlschmidt J, Mrozek K, Mims A, et al
    NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
    Leukemia. 2018 Jun 5. pii: 10.1038/s41375-018-0147.
    PubMed     Abstract available


  558. DONG X, Zhang W, Wu H, Huang J, et al
    Structural basis of DUX4/IGH-driven transactivation.
    Leukemia. 2018;32:1466-1476.
    PubMed     Abstract available


  559. INOUE D, Fujino T, Sheridan P, Zhang YZ, et al
    A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.
    Leukemia. 2018;32:1327-1337.
    PubMed     Abstract available


  560. VERBIEST T, Finnon R, Brown N, Cruz-Garcia L, et al
    Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis.
    Leukemia. 2018;32:1435-1444.
    PubMed     Abstract available


  561. ZHENG L, Xu L, Xu Q, Yu L, et al
    Utx loss causes myeloid transformation.
    Leukemia. 2018;32:1458-1465.
    PubMed     Abstract available


    May 2018
  562. CHEUNG LC, Tickner J, Hughes AM, Skut P, et al
    New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
    Leukemia. 2018 May 8. pii: 10.1038/s41375-018-0144.
    PubMed     Abstract available


  563. MEGGENDORFER M, Cappelli LV, Walter W, Haferlach C, et al
    IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.
    Leukemia. 2018;32:1249-1253.
    PubMed    


  564. DAVIDSSON J, Puschmann A, Tedgard U, Bryder D, et al
    SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.
    Leukemia. 2018;32:1106-1115.
    PubMed     Abstract available


  565. ZHENG W, O'Hear CE, Alli R, Basham JH, et al
    PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
    Leukemia. 2018;32:1157-1167.
    PubMed     Abstract available


  566. JETANI H, Garcia-Cadenas I, Nerreter T, Thomas S, et al
    CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib.
    Leukemia. 2018;32:1168-1179.
    PubMed     Abstract available


  567. ZAMPINI M, Tregnago C, Bisio V, Simula L, et al
    Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.
    Leukemia. 2018;32:1124-1134.
    PubMed     Abstract available


  568. WONG ACH, Rasko JEJ, Wong JJ
    We skip to work: alternative splicing in normal and malignant myelopoiesis.
    Leukemia. 2018;32:1081-1093.
    PubMed     Abstract available


  569. TEFFERI A, Mudireddy M, Mannelli F, Begna KH, et al
    Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.
    Leukemia. 2018;32:1200-1210.
    PubMed     Abstract available


    April 2018
  570. PATNAIK MM, Pierola AA, Vallapureddy R, Yalniz FF, et al
    Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0143.
    PubMed    


  571. HUITING LN, Samaha Y, Zhang GL, Roderick JE, et al
    UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0141.
    PubMed     Abstract available


  572. XIAO W, Rampal R, Zhang Y, Cimera R, et al
    JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0145.
    PubMed    


  573. KAYSER S, Schlenk RF, Platzbecker U
    Management of patients with acute promyelocytic leukemia.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0139.
    PubMed     Abstract available


  574. GARCIA EG, Iyer S, Garcia SP, Loontiens S, et al
    Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0130.
    PubMed    


  575. RENNEVILLE A, Attias P, Thomas X, Bally C, et al
    Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0137.
    PubMed    


  576. DE BIE J, Demeyer S, Alberti-Servera L, Geerdens E, et al
    Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0127.
    PubMed     Abstract available


  577. PASCHKA P, Schlenk RF, Weber D, Benner A, et al
    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0129.
    PubMed     Abstract available


  578. STUDENCKA-TURSKI M, Maubach G, Feige MH, Naumann M, et al
    Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0128.
    PubMed    


  579. WARTIOVAARA-KAUTTO U, Hirvonen EAM, Pitkanen E, Heckman C, et al
    Germline alterations in a consecutive series of acute myeloid leukemia.
    Leukemia. 2018 Apr 10. pii: 10.1038/s41375-018-0049.
    PubMed    


  580. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2018 Apr 7. pii: 10.1038/s41375-018-0032.
    PubMed    


  581. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Abstract available


  582. PATNAIK MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, et al
    A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0121.
    PubMed    


  583. PETER B, Bibi S, Eisenwort G, Wingelhofer B, et al
    Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Leukemia. 2018;32:1016-1022.
    PubMed     Abstract available


  584. MAURA F, Petljak M, Lionetti M, Cifola I, et al
    Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
    Leukemia. 2018;32:1044-1048.
    PubMed    


  585. SANARICO AG, Ronchini C, Croce A, Memmi EM, et al
    The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.
    Leukemia. 2018;32:911-919.
    PubMed     Abstract available


  586. MARSILIO S, Khiabanian H, Fabbri G, Vergani S, et al
    Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.
    Leukemia. 2018;32:1041-1044.
    PubMed    


    March 2018
  587. HOSSEINI MM, Kurtz SE, Abdelhamed S, Mahmood S, et al
    Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
    Leukemia. 2018 Mar 29. pii: 10.1038/s41375-018-0112.
    PubMed     Abstract available


  588. THAN H, Qiao Y, Huang X, Yan D, et al
    Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0050.
    PubMed    


  589. HOJJAT-FARSANGI M, Daneshmanesh AH, Khan AS, Shetye J, et al
    First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0113.
    PubMed    


  590. THI NGOC PC, Tan SH, Tan TK, Chan MM, et al
    Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0110.
    PubMed     Abstract available


  591. GHIA P, Rawstron A
    Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0109.
    PubMed     Abstract available


  592. KUCHENBAUER F, Buske C
    Revisiting thrombocytopenia in acute promyelocytic leukemia.
    Leukemia. 2018 Mar 23. pii: 10.1038/s41375-018-0105.
    PubMed    


  593. RUDAT S, Pfaus A, Cheng YY, Holtmann J, et al
    RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
    Leukemia. 2018 Mar 22. pii: 10.1038/s41375-018-0102.
    PubMed     Abstract available


  594. GENTILE M, Shanafelt TD, Reda G, Mauro FR, et al
    Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0100.
    PubMed    


  595. BURNS MA, Liao ZW, Yamagata N, Pouliot GP, et al
    Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0097.
    PubMed     Abstract available


  596. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Abstract available


  597. QIN YZ, Huang XJ, Zhu HH
    Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Leukemia. 2018 Mar 14. pii: 10.1038/s41375-018-0095.
    PubMed    


  598. GUNNARSSON R, Dilorenzo S, Lundin-Strom KB, Olsson L, et al
    Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 12. pii: 10.1038/s41375-018-0092.
    PubMed     Abstract available


  599. KELLY AD, Madzo J, Madireddi P, Kropf P, et al
    Demethylator phenotypes in acute myeloid leukemia.
    Leukemia. 2018 Mar 7. pii: 10.1038/s41375-018-0084.
    PubMed     Abstract available


  600. GERBOTH S, Frittoli E, Palamidessi A, Baltanas FC, et al
    Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
    Leukemia. 2018;32:820-827.
    PubMed     Abstract available


  601. ANDERSSON EI, Putzer S, Yadav B, Dufva O, et al
    Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Leukemia. 2018;32:774-787.
    PubMed     Abstract available


    February 2018
  602. TAWANA K, Drazer MW, Churpek JE
    Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0051.
    PubMed     Abstract available


  603. MARUFFI M, Sposto R, Oberley MJ, Kysh L, et al
    Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0058.
    PubMed     Abstract available


  604. SAUSSELE S, Hehlmann R, Fabarius A, Jeromin S, et al
    Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
    Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0055.
    PubMed     Abstract available


  605. ALI A, Penneroux J, Dal Bello R Jr, Masse A, et al
    Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
    Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0076.
    PubMed    


  606. PETROV JC, Wada M, Pinz KG, Yan LE, et al
    Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0075.
    PubMed     Abstract available


  607. HNIZDA A, Fabry M, Moriyama T, Pachl P, et al
    Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0073.
    PubMed     Abstract available


  608. EISFELD AK, Kohlschmidt J, Mrozek K, Blachly JS, et al
    Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0068.
    PubMed     Abstract available


  609. BICCLER JL, Ostgard LSG, Severinsen MT, Marcher CW, et al
    Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0054.
    PubMed    


  610. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
    Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0034.
    PubMed     Abstract available


  611. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
    Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0039.
    PubMed     Abstract available


  612. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
    Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0035.
    PubMed     Abstract available


  613. LAVALLEE VP, Chagraoui J, MacRae T, Marquis M, et al
    Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0069.
    PubMed     Abstract available


  614. DAVER N, Boddu P, Garcia-Manero G, Yadav SS, et al
    Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0070.
    PubMed     Abstract available


  615. L ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0033.
    PubMed     Abstract available


  616. RASCHE M, Zimmermann M, Borschel L, Bourquin JP, et al
    Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0071.
    PubMed     Abstract available


  617. STRATI P, Ferrajoli A, Wierda WG, Jain N, et al
    Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
    Leukemia. 2018 Feb 20. pii: 10.1038/s41375-018-0059.
    PubMed    


  618. CRAMER SD, Hixon JA, Andrews C, Porter RJ, et al
    Mutant IL-7Ralpha and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.
    Leukemia. 2018 Feb 15. pii: 10.1038/s41375-017-0001.
    PubMed    


  619. SUAREZ-GONZALEZ J, Martinez-Laperche C, Martinez N, Rodriguez-Macias G, et al
    Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis.
    Leukemia. 2018 Feb 5. pii: 10.1038/s41375-018-0042.
    PubMed    


  620. PENG D, Wang H, Li L, Ma X, et al
    miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0015.
    PubMed     Abstract available


  621. LA STARZA R, Messina M, Gianfelici V, Pierini V, et al
    High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0031.
    PubMed    


  622. WINGELHOFER B, Maurer B, Heyes EC, Cumaraswamy AA, et al
    Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0005.
    PubMed     Abstract available


  623. MALCIKOVA J, Tausch E, Rossi D, Sutton LA, et al
    ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0007.
    PubMed     Abstract available


  624. BALASUBRAMANIAN SK, Aly M, Nagata Y, Bat T, et al
    Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.
    Leukemia. 2018;32:550-553.
    PubMed    


  625. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
    Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
    Leukemia. 2018;32:364-375.
    PubMed     Abstract available


  626. STENGEL A, Kern W, Meggendorfer M, Nadarajah N, et al
    Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.
    Leukemia. 2018;32:295-302.
    PubMed     Abstract available


  627. KUBESOVA B, Pavlova S, Malcikova J, Kabathova J, et al
    Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
    Leukemia. 2018;32:450-461.
    PubMed     Abstract available


  628. DEANGELO DJ, George TI, Linder A, Langford C, et al
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
    Leukemia. 2018;32:470-478.
    PubMed     Abstract available


  629. LIU E, Tong Y, Dotti G, Shaim H, et al
    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Leukemia. 2018;32:520-531.
    PubMed     Abstract available


  630. MEYER C, Burmeister T, Groger D, Tsaur G, et al
    The MLL recombinome of acute leukemias in 2017.
    Leukemia. 2018;32:273-284.
    PubMed     Abstract available


  631. GARRIDO CASTRO P, van Roon EHJ, Pinhancos SS, Trentin L, et al
    The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Leukemia. 2018;32:323-331.
    PubMed     Abstract available


  632. KAUSHIK S, Liu F, Veazey KJ, Gao G, et al
    Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
    Leukemia. 2018;32:499-509.
    PubMed     Abstract available


    January 2018
  633. SUN X, Ren Y, Gunawan S, Teng P, et al
    Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099.
    Leukemia. 2018 Jan 30. pii: 10.1038/s41375-018-0020.
    PubMed    


  634. JO S, Lee JH, Mattei JJ, Barrett DM, et al
    Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
    Leukemia. 2018 Jan 5. pii: leu2017312. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  635. PIETTE C, Suciu S, Clappier E, Bertrand Y, et al
    Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.
    Leukemia. 2018;32:244-248.
    PubMed    


  636. BUONTEMPO F, McCubrey JA, Orsini E, Ruzzene M, et al
    Therapeutic targeting of CK2 in acute and chronic leukemias.
    Leukemia. 2018;32:1-10.
    PubMed     Abstract available


  637. BRAZDILOVA K, Plevova K, Skuhrova Francova H, Kockova H, et al
    Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.
    Leukemia. 2018;32:234-236.
    PubMed    


  638. BODDU P, Jorgensen J, Kantarjian H, Borthakur G, et al
    Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
    Leukemia. 2018;32:241-244.
    PubMed    


  639. GU S, Sayad A, Chan G, Yang W, et al
    SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Leukemia. 2018;32:203-213.
    PubMed     Abstract available


  640. MINGAY M, Chaturvedi A, Bilenky M, Cao Q, et al
    Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia.
    Leukemia. 2018;32:11-20.
    PubMed     Abstract available


  641. GOLE B, Mian E, Rall M, Wiesmuller L, et al
    Base excision repair proteins couple activation-induced cytidine deaminase and endonuclease G during replication stress-induced MLL destabilization.
    Leukemia. 2018;32:159-167.
    PubMed     Abstract available


  642. BROWN JR, Hillmen P, O'Brien S, Barrientos JC, et al
    Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
    Leukemia. 2018;32:83-91.
    PubMed     Abstract available


  643. VILLARESE P, Lours C, Trinquand A, Le Noir S, et al
    TCRalpha rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.
    Leukemia. 2018;32:61-71.
    PubMed     Abstract available


  644. SUN L, Shi Y, Wang G, Wang X, et al
    PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
    Leukemia. 2018;32:184-193.
    PubMed     Abstract available


  645. WELSH SJ, Churchman ML, Togni M, Mullighan CG, et al
    Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
    Leukemia. 2018;32:38-48.
    PubMed     Abstract available


    December 2017
  646. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
    Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).
    Leukemia. 2017 Dec 18. pii: leu2017341. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  647. BU J, Chen A, Yan X, He F, et al
    SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
    Leukemia. 2017 Dec 18. pii: leu2017339. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  648. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
    Chromothripsis in acute myeloid leukemia: Biological features and impact on survival.
    Leukemia. 2017 Dec 18. pii: leu2017351. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  649. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
    Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Leukemia. 2017 Dec 18. pii: leu2017350. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  650. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2017 Dec 12. pii: leu2017349. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  651. TIRADO-GONZALEZ I, Czlonka E, Nevmerzhitskaya A, Soetopo D, et al
    CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.
    Leukemia. 2017 Dec 6. pii: leu2017346. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  652. DRIESSEN EMC, de Lorenzo P, Campbell M, Felice M, et al
    Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.
    Leukemia. 2017;31:2854.
    PubMed     Abstract available


  653. GRZES KM, Swamy M, Hukelmann JL, Emslie E, et al
    Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
    Leukemia. 2017;31:2771-2779.
    PubMed     Abstract available


  654. GARCIA-MANERO G, Sekeres MA, Egyed M, Breccia M, et al
    A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts.
    Leukemia. 2017;31:2799-2806.
    PubMed     Abstract available


  655. TESIO M, Trinquand A, Ballerini P, Hypolite G, et al
    Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.
    Leukemia. 2017;31:2594-2600.
    PubMed     Abstract available


  656. ELDER A, Bomken S, Wilson I, Blair HJ, et al
    Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.
    Leukemia. 2017;31:2577-2586.
    PubMed     Abstract available


  657. DELGADO-MARTIN C, Meyer LK, Huang BJ, Shimano KA, et al
    JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Leukemia. 2017;31:2568-2576.
    PubMed     Abstract available


  658. RASCHE M, von Neuhoff C, Dworzak M, Bourquin JP, et al
    Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.
    Leukemia. 2017;31:2807-2814.
    PubMed     Abstract available


  659. ZHANG H, Reister Schultz A, Luty S, Rofelty A, et al
    Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.
    Leukemia. 2017;31:2752-2760.
    PubMed     Abstract available


  660. LYU Y, Lou J, Yang Y, Feng J, et al
    Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
    Leukemia. 2017;31:2543-2551.
    PubMed     Abstract available


  661. YOKOTA A, Hirai H, Shoji T, Maekawa T, et al
    Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.
    Leukemia. 2017;31:2742-2751.
    PubMed     Abstract available


    November 2017
  662. LABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2017 Nov 28. pii: leu2017337. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  663. NIMMAGADDA SC, Frey S, Edelmann B, Hellmich C, et al
    Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
    Leukemia. 2017 Nov 7. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  664. LHERMITTE L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, et al
    Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.
    Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  665. WALF-VORDERWULBECKE V, Pearce K, Brooks T, Hubank M, et al
    Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
    Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  666. HADZIJUSUFOVIC E, Albrecht-Schgoer K, Huber K, Hoermann G, et al
    Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
    Leukemia. 2017;31:2388-2397.
    PubMed     Abstract available


  667. PULIKKAN JA, Tenen DG, Behre G
    C/EBPalpha deregulation as a paradigm for leukemogenesis.
    Leukemia. 2017;31:2279-2285.
    PubMed     Abstract available


  668. LIU X, Rothe K, Yen R, Fruhstorfer C, et al
    A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.
    Leukemia. 2017;31:2376-2387.
    PubMed     Abstract available


  669. THIEL VN, Giaimo BD, Schwarz P, Soller K, et al
    Heterodimerization of AML1/ETO with CBFbeta is required for leukemogenesis but not for myeloproliferation.
    Leukemia. 2017;31:2491-2502.
    PubMed     Abstract available


  670. O'LEARY HA, Capitano M, Cooper S, Mantel C, et al
    DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.
    Leukemia. 2017;31:2468-2478.
    PubMed     Abstract available


  671. HOWARD DR, Munir T, McParland L, Rawstron AC, et al
    Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
    Leukemia. 2017;31:2416-2425.
    PubMed     Abstract available


  672. SAVINO AM, Sarno J, Trentin L, Vieri M, et al
    The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
    Leukemia. 2017;31:2365-2375.
    PubMed     Abstract available


  673. KRAMER AC, Kothari A, Wilson WC, Celik H, et al
    Dnmt3a regulates T-cell development and suppresses T-ALL transformation.
    Leukemia. 2017;31:2479-2490.
    PubMed     Abstract available


  674. ABRAHAM M, Klein S, Bulvik B, Wald H, et al
    The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
    Leukemia. 2017;31:2336-2346.
    PubMed     Abstract available


  675. HA VL, Luong A, Li F, Casero D, et al
    The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.
    Leukemia. 2017;31:2503-2514.
    PubMed     Abstract available


  676. DELL'AVERSANA C, Giorgio C, D'Amato L, Lania G, et al
    miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.
    Leukemia. 2017;31:2315-2325.
    PubMed     Abstract available


    October 2017
  677. SAID B, Gilles S, Weisdorf D, Rashidi A, et al
    The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia.
    Leukemia. 2017 Oct 31. doi: 10.1038/leu.2017.
    PubMed    


  678. YAN F, Shen N, Pang JX, Zhao N, et al
    A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.
    Leukemia. 2017 Oct 10. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  679. TOPP MS, Stelljes M, Zugmaier G, Barnette P, et al
    Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 9. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  680. JERCHEL IS, Hoogkamer AQ, Aries IM, Steeghs EMP, et al
    RAS pathway mutations as predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 3. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  681. LI Z, Abraham BJ, Berezovskaya A, Farah N, et al
    APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
    Leukemia. 2017;31:2057-2064.
    PubMed     Abstract available


  682. MUNIR T, Howard DR, McParland L, Pocock C, et al
    Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Leukemia. 2017;31:2085-2093.
    PubMed     Abstract available


  683. JU HQ, Zhan G, Huang A, Sun Y, et al
    ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
    Leukemia. 2017;31:2143-2150.
    PubMed     Abstract available


  684. DUELL J, Dittrich M, Bedke T, Mueller T, et al
    Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
    Leukemia. 2017;31:2181-2190.
    PubMed     Abstract available


  685. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Abstract available


    September 2017
  686. FUJITA S, Honma D, Adachi N, Araki K, et al
    Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
    Leukemia. 2017 Sep 27. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  687. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2017 Sep 25. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  688. BENEDETTI D, Tissino E, Pozzo F, Bittolo T, et al
    NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-kB pathways.
    Leukemia. 2017 Sep 22. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  689. JO S, Lee JH, Mattei JJ, Barrett DM, et al
    Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  690. DEL GIUDICE I, Rigolin GM, Raponi S, Cafforio L, et al
    Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low and very-low risk genetic profile.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  691. NADEU F, Clot G, Delgado J, Martin-Garcia D, et al
    Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  692. HOSPITAL MA, Jacquel A, Mazed F, Saland E, et al
    RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  693. SAKURA T, Hayakawa F, Sugiura I, Murayama T, et al
    High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  694. WAIBEL M, Vervoort SJ, Kong IY, Heinzel S, et al
    Epigenetic targeting of Notch1 driven transcription using the HDACi panobinostat is a potential therapy against T cell acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  695. TAKAO S, Chien W, Madan V, Lin DC, et al
    Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 14. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  696. MARNETH AE, Prange KHM, Al Hinai ASA, Bergevoet SM, et al
    C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
    Leukemia. 2017 Sep 5. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  697. RINKE J, Muller JP, Blaess MF, Chase A, et al
    Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
    Leukemia. 2017;31:1936-1943.
    PubMed     Abstract available


  698. KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
    The clonal origins of leukemic progression of myelodysplasia.
    Leukemia. 2017;31:1928-1935.
    PubMed     Abstract available


  699. SAENZ DT, Fiskus W, Qian Y, Manshouri T, et al
    Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Leukemia. 2017;31:1951-1961.
    PubMed     Abstract available


  700. RONCHINI C, Brozzi A, Riva L, Luzi L, et al
    PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.
    Leukemia. 2017;31:1975-1986.
    PubMed     Abstract available


    August 2017
  701. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
    Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Aug 30. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  702. JYOTSANA N, Sharma A, Chaturvedi A, Scherr M, et al
    RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.
    Leukemia. 2017 Aug 22. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  703. ZHAO L, Alkadi H, Kwon EM, Zhen T, et al
    The C-terminal multimerization domain is essential for leukemia development by CBFbeta-SMMHC in a mouse knockin model.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  704. TOFT N, Birgens H, Abrahamsson J, Griskevicius L, et al
    Results of NOPHO ALL2008 treatment for patients 1-45 years with acute lymphoblastic leukemia.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  705. PENA-MARTINEZ P, Eriksson M, Ramakrishnan R, Chapellier M, et al
    Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  706. KUMAR B, Garcia M, Weng L, Jung X, et al
    Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
    Leukemia. 2017 Aug 17. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  707. ARTESI M, Marcais A, Durkin K, Rosewick N, et al
    Monitoring molecular response in adult t-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.
    Leukemia. 2017 Aug 16. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  708. HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
    Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  709. HEHLMANN R, Lauseker M, Saussele S, Pfirrmann M, et al
    Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  710. REITER K, Polzer H, Krupka C, Maiser A, et al
    Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  711. MASCIARELLI S, Capuano E, Ottone T, Divona M, et al
    'Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress'.
    Leukemia. 2017 Aug 4. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  712. RAFIQ S, Purdon TJ, Daniyan AF, Koneru M, et al
    Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
    Leukemia. 2017;31:1788-1797.
    PubMed     Abstract available


  713. DRENNAN S, D'Avola A, Gao Y, Weigel C, et al
    IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.
    Leukemia. 2017;31:1686-1694.
    PubMed     Abstract available


    July 2017
  714. KIM HG, LeGrand J, Swindle CS, Nick HJ, et al
    The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  715. YIGIT B, Wang N, Chen SS, Chiorazzi N, et al
    Inhibition of Reactive oxygen species (ROS) limits expansion of chronic lymphocytic leukemia cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  716. TEH TC, Nguyen NY, Moujalled DM, Segal D, et al
    Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  717. GIRARDI T, Vereecke S, Sulima SO, Khan Y, et al
    The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  718. XIA F, Zhang Y, Xie L, Jiang H, et al
    B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  719. SOPPER S, Mustjoki S, Gjertsen BT, Giles F, et al
    NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  720. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
    Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed    


  721. BECK D, Thoms JAI, Palu C, Herold T, et al
    A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
    Leukemia. 2017 Jul 4. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  722. HOURIGAN CS, Gale RP, Gormley NJ, Ossenkoppele GJ, et al
    Measurable residual disease testing in acute myeloid leukaemia.
    Leukemia. 2017;31:1482-1490.
    PubMed     Abstract available


  723. CUTLER JA, Tahir R, Sreenivasamurthy SK, Mitchell C, et al
    Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
    Leukemia. 2017;31:1513-1524.
    PubMed     Abstract available


  724. RIBEIRO ST, Tesio M, Ribot JC, Macintyre E, et al
    Casein kinase 2 controls the survival of normal thymic and leukemic gammadelta T cells via promotion of AKT signaling.
    Leukemia. 2017;31:1603-1610.
    PubMed     Abstract available


    June 2017
  725. ANGENENDT L, Reuter S, Kentrup D, Benk AS, et al
    An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  726. YABE T, Azuma F, Kashiwase K, Matsumoto K, et al
    HLA-DPB1 mismatch induces a graft-versus-leukemia (GVL) effect without severe acute GVHD after single-unit umbilical cord blood transplantation.
    Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  727. TIAO G, Improgo MR, Kasar S, Poh W, et al
    Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
    Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  728. GAIDZIK VI, Weber D, Paschka P, Kaumanns A, et al
    DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
    Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  729. ZHANG Q, Ball MC, Zhao Y, Balasis M, et al
    Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.
    Leukemia. 2017 Jun 21. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  730. RIO-MACHIN A, Gomez-Lopez G, Munoz J, Garcia-Martinez F, et al
    The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.
    Leukemia. 2017 Jun 20. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  731. GODWIN CD, Gale RP, Walter RB
    Gemtuzumab ozogamicin in acute myeloid leukemia.
    Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  732. SANTINI V, Allione B, Zini G, Gioia D, et al
    A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
    Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  733. BURNS A, Alsolami R, Becq J, Timbs A, et al
    Whole genome sequencing of chronic lymphocytic leukemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.
    Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  734. MARTINEZ-CUADRON D, Montesinos P, Vellenga E, Bernal T, et al
    Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
    Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  735. PROMOD ST, Johnson DP, Bennett SE, Dennis EM, et al
    HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Jun 5. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  736. HAHN M, Burckert JP, Luttenberger CA, Klebow S, et al
    Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappaB signaling.
    Leukemia. 2017 Jun 1. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  737. USTUN C, Giannotti F, Zhang MJ, Wang HL, et al
    Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
    Leukemia. 2017;31:1408-1414.
    PubMed     Abstract available


  738. HERNDON TM, Chen SS, Saba NS, Valdez J, et al
    Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
    Leukemia. 2017;31:1340-1347.
    PubMed     Abstract available


  739. YAN F, Shen N, Pang JX, Zhang YW, et al
    Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.
    Leukemia. 2017;31:1434-1442.
    PubMed     Abstract available


  740. CHENG G, Liu F, Asai T, Lai F, et al
    Loss of p300 accelerates MDS-associated leukemogenesis.
    Leukemia. 2017;31:1382-1390.
    PubMed     Abstract available


  741. RODMAN C, Almeida-Porada G, George SK, Moon J, et al
    In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells.
    Leukemia. 2017;31:1398-1407.
    PubMed     Abstract available


  742. CARTER MJ, Cox KL, Blakemore SJ, Turaj AH, et al
    PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
    Leukemia. 2017;31:1423-1433.
    PubMed     Abstract available


    May 2017
  743. HALPERN AB, Othus M, Huebner EM, Buckley SA, et al
    Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  744. HA JS, Do YR, Ki CS, Lee C, et al
    Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  745. PATEL B, Przychodzen B, Thota S, Radivoyevitch T, et al
    Genomic determinants of chronic myelomonocytic leukemia.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  746. HEILMANN AM, Schrock AB, He J, Nahas M, et al
    Novel PDGFRB fusions in childhood B and T acute lymphoblastic leukemia.
    Leukemia. 2017 May 29. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  747. MA Z, Zhao X, Huang J, Jia X, et al
    A critical role of periostin in B-cell acute lymphoblastic leukemia.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  748. BERNSON E, Hallner A, Sander FE, Wilsson O, et al
    Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  749. HINZE L, Moricke A, Zimmermann M, Junk S, et al
    Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  750. CHEN L, Mao H, Zhang J, Chu J, et al
    Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
    Leukemia. 2017 May 12. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  751. PAN J, Yang J, Deng B, Zhao X, et al
    High efficacy and safety of low dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Leukemia. 2017 May 11. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  752. ROSSETTI C, Picardi E, Ye M, Camilli G, et al
    RNA editing signature during myeloid leukemia cell differentiation.
    Leukemia. 2017 May 9. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  753. HASAN K, Yu J, Chen L, Cui B, et al
    Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  754. YU J, Chen L, Chen Y, Hasan K, et al
    Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
    Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  755. SLINGER E, Thijssen R, Kater AP, Eldering E, et al
    Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  756. LONG J, Fang WY, Chang L, Gao WH, et al
    Targeting HDAC3, new partner protein of AKT in the reversal of chemo-resistance in acute myeloid leukemia via DNA damage response.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  757. GUNNARSSON N, Hoglund M, Stenke L, Sandin F, et al
    No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia-a population-based study in Sweden.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  758. EIRING AM, Page BDG, Kraft IL, Mason CC, et al
    Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Leukemia. 2017;31:1253-1254.
    PubMed    


  759. LEROY E, Constantinescu SN
    Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition.
    Leukemia. 2017;31:1023-1038.
    PubMed     Abstract available


  760. KAZIANKA L, Drucker C, Skrabs C, Thomas W, et al
    Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
    Leukemia. 2017;31:1117-1122.
    PubMed     Abstract available


  761. MALANI D, Murumagi A, Yadav B, Kontro M, et al
    Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
    Leukemia. 2017;31:1187-1195.
    PubMed     Abstract available


  762. LIU TH, Tang YJ, Huang Y, Wang L, et al
    Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin.
    Leukemia. 2017;31:1079-1086.
    PubMed     Abstract available


    April 2017
  763. CAZZANIGA G, Bisanti L, Randi G, Deandrea S, et al
    Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster.
    Leukemia. 2017 Apr 27. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  764. ROSENQUIST R, Ghia P, Hadzidimitriou A, Sutton LA, et al
    Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: Updated eric recommendations.
    Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  765. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
    Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  766. KONGTIM P, Adekola K, Milton DR, Ramlal R, et al
    Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Leukemia. 2017 Apr 12. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  767. HAN SH, Kim SH, Kim HJ, Lee Y, et al
    Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
    Leukemia. 2017 Apr 11. doi: 10.1038/leu.2017.
    PubMed    


  768. JONES D, Woyach JA, Zhao W, Caruthers S, et al
    PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  769. SILVA P, Neumann M, Schroeder MP, Vosberg S, et al
    Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  770. HEATH EM, Chan SM, Minden MD, Murphy T, et al
    Biological and clinical consequences of NPM1 mutations in AML.
    Leukemia. 2017;31:798-807.
    PubMed     Abstract available


  771. VALENT P, Sotlar K, Blatt K, Hartmann K, et al
    Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
    Leukemia. 2017;31:788-797.
    PubMed     Abstract available


  772. SCHUTZ C, Inselmann S, Sausslele S, Dietz CT, et al
    Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
    Leukemia. 2017;31:829-836.
    PubMed     Abstract available


    March 2017
  773. HEROLD S, Kuhn M, Bonin MV, Stange T, et al
    Donor cell leukemia-Evidence for multiple pre-leukemic clones and parallel long term clonal evolution in donor and recipient.
    Leukemia. 2017 Mar 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  774. ANADON C, van Tetering G, Ferreira HJ, Moutinho C, et al
    Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  775. COSSON A, Chapiro E, Bougacha N, Lambert J, et al
    Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: Analysis of the central role of XPO1.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  776. MONTALBAN-BRAVO G, Huang X, Naqvi K, Jabbour E, et al
    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed    


  777. WALKER CJ, Eisfeld AK, Genutis LK, Bainazar M, et al
    No evidence for microsatellite instability in acute myeloid leukemia.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  778. KAYSER S, Krzykalla J, Elliott MA, Norsworthy K, et al
    Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  779. ZHOU H, Mak PY, Mu H, Mak DH, et al
    Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  780. EISFELD AK, Mrozek K, Kohlschmidt J, Nicolet D, et al
    The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  781. POZZO F, Bittolo T, Vendramini E, Bomben R, et al
    NOTCH1 mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin-1 and ribosome associated components.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  782. KOEFFLER HP, Leong G
    Preleukemia: one name, many meanings.
    Leukemia. 2017;31:534-542.
    PubMed     Abstract available


  783. SAENZ DT, Fiskus W, Manshouri T, Rajapakshe K, et al
    BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Leukemia. 2017;31:678-687.
    PubMed     Abstract available


  784. QAZILBASH MH, Wieder E, Thall PF, Wang X, et al
    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
    Leukemia. 2017;31:697-704.
    PubMed     Abstract available


  785. STRUSKI S, Lagarde S, Bories P, Puiseux C, et al
    NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Leukemia. 2017;31:565-572.
    PubMed     Abstract available


  786. STENGEL A, Kern W, Haferlach T, Meggendorfer M, et al
    The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Leukemia. 2017;31:705-711.
    PubMed     Abstract available


  787. MCCRACKEN AN, McMonigle RJ, Tessier J, Fransson R, et al
    Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
    Leukemia. 2017;31:669-677.
    PubMed     Abstract available


  788. EDELMANN J, Tausch E, Landau DA, Robrecht S, et al
    Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
    Leukemia. 2017;31:734-738.
    PubMed    


    February 2017
  789. MEDEIROS BC, Fathi AT, DiNardo CD, Pollyea DA, et al
    Isocitrate dehydrogenase mutations in myeloid malignancies.
    Leukemia. 2017;31:272-281.
    PubMed     Abstract available


  790. BURNETT AK, Russell NH, Hills RK, Kell J, et al
    A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
    Leukemia. 2017;31:310-317.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: